<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="molecules-26-01107-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">molecules-26-01107-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Effects of essential oils (EOs) on neurodegenerative diseases.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">No.</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Disease</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Study</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Source of Essential Oils</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Ref</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Method</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Findings</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">Conclusions and/or Recommendations</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">1.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Ajuga chamaecistus subsp scoparia (Boiss.)</italic> Rech.f.
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B64-molecules-26-01107" ref-type="bibr">64</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling [Gas chromatography (GC), Gas chromatography–mass spectrometry (GC–MS), High-performance liquid chromatography with diode-array detection (HPLC–DAD)]</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Major constituents in the EO—Spathulenol (18.0%), thymol (15.1%), octen-3-ol (14.3%), and linalool oxide (11.2%).</p>
      </list-item>
      <list-item>
       <p>Inhibit the activity of AChE (1.96 mg gallic acid equivalents/g), BChE (2.2 mg gallic acid equivalents/g).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This study should be extended to individual constituents of the EO and extracts of 
        <italic>A. chamaecistus.</italic>
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">2.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Allium tuncelianum</italic> (Amaryllidaceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B65-molecules-26-01107" ref-type="bibr">65</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling [Gas chromatography–flame ionisation detector (GC–FID), GC–MS)]</p>
      </list-item>
      <list-item>
       <p>Anti-lipid peroxidation activity</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Major components—Diallyl disulfide (49.8%), diallyl trisulfide (27.9%) and allyl methyl trisulfide (6.9%).</p>
      </list-item>
      <list-item>
       <p>EO inhibition against BChE (28.65 ± 2.58%) and AChE (7.59 ± 2.90%) at 100 µg/mL.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>A. tuncelianum</italic> could be a novel potency source of native antioxidant and anticholinesterase components.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">3.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Aloysia citrodora Palau</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B66-molecules-26-01107" ref-type="bibr">66</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Radioligand binding profile</p>
      </list-item>
      <list-item>
       <p>MTT cell viability assay</p>
      </list-item>
      <list-item>
       <p>Treatment of cell cultures with Aβ</p>
      </list-item>
      <list-item>
       <p>CytoTox 96 nonradioactive assay</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major chemical components—limonene, geranial, neral, 1, 8-cineole, curcumene, spathulenol and caryophyllene oxide.</p>
      </list-item>
      <list-item>
       <p>
        <italic>A. citrodora</italic> leaf EO inhibited [3H] nicotine binding to well-washed rat forebrain membranes, and increased iron-chelation in vitro.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>A. citrodora</italic> EO displays effective antioxidant, radical-scavenging activities and significant protective properties vs both hydrogen peroxide- and β-amyloid-induced neurotoxicity.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>A. citrodora</italic> EO possess nicotinic cholinergic, oxidative and significant neuroprotective activities. These activities are of relevance to potential AD therapy, as well as other.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">4.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Artemisia macrocephala</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B26-molecules-26-01107" ref-type="bibr">26</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major components were α-humulene (46.3%), β-caryophyllene (9.3%), α-copaene (8.2%), β-myrcene (4.3%), 
        <italic>Z</italic>(
        <italic>E</italic>)-α-farnesene (3.7%), and calarene (3.5%).
       </p>
      </list-item>
      <list-item>
       <p>Diverse volatile organic constituents (VOCs) of 
        <italic>A. maderaspatana</italic> have significant AChE inhibitory activity (IC
        <sub>50</sub> value = 31.33 ± 1.03 mg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results of this study confirm the beneficial use.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">5.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Artemisia maderaspatana</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B67-molecules-26-01107" ref-type="bibr">67</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major components were α-humulene (46.3%), β-caryophyllene (9.3%), α-copaene (8.2%), β-myrcene (4.3%), 
        <italic>Z</italic>(
        <italic>E</italic>)-a-farnesene (3.7%), and calarene (3.5%).
       </p>
      </list-item>
      <list-item>
       <p>The experimental results showed that diverse VOCs of 
        <italic>A. maderaspatana</italic> have significant AChE inhibitory activity (IC
        <sub>50</sub> value of 31.33 ± 1.03 mg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The possibility of novel AChE inhibitors might exist in VOCs of this plant.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">6.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Artemisia absinthium</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B27-molecules-26-01107" ref-type="bibr">27</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Niosomal vesicles employing phosphatidylcholine, span 60, cholesterol and distearoylphosphatidylethanolamine with covalently linked polyethylene glycol of molecular weight 2000 (DSPE-PEG2000) by the thin-film method. 
        <italic>A. absinthium</italic> was loaded into the niosomes.
       </p>
      </list-item>
      <list-item>
       <p>Inhibitory effect on aggregation of Aβ peptides using Thioflavin T fluorescence and atomic force microscopy.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Niosomes containing 
        <italic>A. absinthium</italic> have a size of 174 ± 2.56 nm, the encapsulation efficiency of 66.73%, zeta potential of −26.5 ± 1/42 mV and polydispersity index (PDI) of 0.373 ± 0/02.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The nano-niosomes containing EO from art 
        <italic>A. absinthium</italic> has the capability to preclude amyloid development.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">7.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Boswellia dalzielii</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B68-molecules-26-01107" ref-type="bibr">68</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>Anti-inflammatory activity (5-lipoxygenase (LOX) inhibition assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Fifty compounds were identified, including 3-carene (27.72%) and α-pinene (15.18%). 2,5-Dihydroxy acetophenone and β-
        <sc>d</sc>-xylopyranose were identified in the methanol extract.
       </p>
      </list-item>
      <list-item>
       <p>IC
        <sub>50</sub> = 35.10 mg/L for antixanthine oxidase and 28.01 mg/L for anti-5-lipoxygenase.
       </p>
      </list-item>
      <list-item>
       <p>For AChE inhibition, the best IC
        <sub>50</sub> (76.20 and 67.10 mg/L) were observed, respectively, with an ethyl acetate extract and the EO. At 50 mg/L, the dichloromethane extract inhibited OVCAR-3 cell lines by 65.10%, while cyclohexane extract inhibited IGROV-1 cell lines by 92.60%.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The ethyl acetate and methanol extracts could be considered as potential alternatives for use in dietary supplements. They have a natural antioxidant, antihyperuricemic and anti-inflammatory activities.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">8.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Chamaecyparis obtusa</italic>
     <break/>
     <italic>Cryptomeria japonica</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B69-molecules-26-01107" ref-type="bibr">69</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling [(GC–MS, Nuclear magnetic resonance (NMR)]</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Anti-AChE activity of 
        <italic>C. japonica</italic> with 64.8% of inhibition at 100 μg/mL.
       </p>
      </list-item>
      <list-item>
       <p>The active principles of anti-AChE were investigated by activity-guided fractionation, and kaur-16-ene, nezukol and ferruginol were successfully identified, the IC
        <sub>50</sub> values were 640, 300 and 95 µM, respectively.
       </p>
      </list-item>
      <list-item>
       <p>Kaur-16-ene and nezukol inhibited AChE in the mixed type mode, while ferruginol inhibited it in the competitive mode. In addition, nezukol and ferruginol showed anti-BChE activity, the IC
        <sub>50</sub> values were 155 and 22 μM, respectively.
       </p>
      </list-item>
      <list-item>
       <p>Ethyl acetate extract of 
        <italic>C. obtusa</italic> showed anti-AChE activity of 37.7% inhibition at 100 μg/mL. The active principle was determined to be (−)-hinokinin by activity-guided fractionation and the IC
        <sub>50</sub> value was 176 μM.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The leaf of 
        <italic>C. japonica</italic> and heartwood of 
        <italic>C. obtusa</italic> may be suitable agents for AD therapy when administered through the nasal system as an aroma supplement.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">9.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cinnamomum tamala</italic> (Buch.-Ham.)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B18-molecules-26-01107" ref-type="bibr">18</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling [(High-performance liquid chromatography–photodiode array detection (HPLC-PDA)]</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay and thin-layer chromatography (TLC) bio-autography)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>HPLC analysis confirmed the presence of linalool in 
        <italic>C. tamala</italic> EO.
       </p>
      </list-item>
      <list-item>
       <p>The cinnamon oil obtained from leaves of 
        <italic>C. tamala</italic> possess maximum inhibition against AChE (IC
        <sub>50</sub>: 94.54 ± 0.774 µg/mL) and BChE (IC
        <sub>50</sub>: 135.56 ± 0.912 µg/mL). The result also explains that 
        <italic>C. tamala</italic> is more sensitive to AChE enzyme than the BChE.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>C. tamala</italic> may be explored as an anti-cholinesterase agent further for the better and safer management of ADs.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">10.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cinnamomum zeylanicum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B19-molecules-26-01107" ref-type="bibr">19</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Monoamine oxidase (MAO)-A and MAO-B inhibitory activity (fluorometric assay)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>Inhibition of self- and Cu
        <sup>2+</sup>-induced Aβ1–42 peptide aggregation (Thioflavin T-fluorometric assay)
       </p>
      </list-item>
      <list-item>
       <p>Tyrosinase inhibitory activity (L-dopa)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Twenty-two components were identified representing 99.79% of the oil. (
        <italic>E</italic>)-Cinnamaldehyde (CAL) (81.39%) and (
        <italic>E</italic>)-cinnamyl acetate (CAS) (4.20%) were determined as the major compounds.
       </p>
      </list-item>
      <list-item>
       <p>The oil and the major compounds, CAL and CAS, showed over 78.0% inhibitory activity on cholinesterases.</p>
      </list-item>
      <list-item>
       <p>In MAO A and MAO-B inhibition assay, both oil (96.44% and 95.96%, respectively) and CAL (96.32% and 96.29%, respectively) showed remarkable activity as high as rasagiline (97.42% and 97.38%, respectively).</p>
      </list-item>
      <list-item>
       <p>The oil also showed 57.78% and 84.53% inhibitory activity in self- and Cu
        <sup>2+</sup> induced aggregation of Aβ1–42, respectively. In tyrosinase inhibition assay, CAL (83.75%) and CAS (45.58%) showed higher activity than that of the oil (18.08%).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Total oil exhibited remarkable anti-Alzheimer and skin whitening activity (over 80%).</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">11.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Citrus Sinensis [L.] Osbeck</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B70-molecules-26-01107" ref-type="bibr">70</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE)</p>
      </list-item>
      <list-item>
       <p>MAO inhibition assay</p>
      </list-item>
      <list-item>
       <p>Lipid peroxidation assay</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Forty-four compounds were identified in peels and seed EOs, respectively.</p>
      </list-item>
      <list-item>
       <p>The EOs inhibited AChE, BChE and MAO in a dose-dependent manner. Both EOs inhibited AChE activity. However, peel EO (IC
        <sub>50</sub> = 2.64 μg/mL) had significantly (
        <italic>p</italic> &lt; 0.05) higher inhibition than that of the seeds (IC
        <sub>50</sub> = 3.54 μg/ mL).
       </p>
      </list-item>
      <list-item>
       <p>Similarly, the peel EO (IC
        <sub>50</sub> of 2.61 μg/mL) had higher BChE inhibitory ability than seed EO (IC
        <sub>50</sub> = 3.52 μg/ mL).
       </p>
      </list-item>
      <list-item>
       <p>MAO activity was inhibited compared to the reference test when the EO were added to the sample test. However, the EO from the seeds (IC
        <sub>50</sub> = 6.93 μg/mL) had a significantly (
        <italic>p</italic> &lt; 0.05) higher inhibitory ability compared to peel EO (IC
        <sub>50</sub> = 8.53 μg/mL).
       </p>
      </list-item>
      <list-item>
       <p>In addition, EOs significantly (
        <italic>p</italic> &lt; 0.05) inhibited malondialdehyde (MDA) produced in the brain homogenates to 168.21 and 141.47% for peel and seed EOs, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EOs from sweet orange peels and seeds inhibited cholinergic and monoaminergic enzymes and exhibited antioxidant.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">12.</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Citrus aurantifolia Swingle,</italic>
     <break/>
     <italic>C. aurantium L.</italic>
     <break/>
     <italic>C. bergamia Risso and Poit.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B71-molecules-26-01107" ref-type="bibr">71</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—spectrophotometric method)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The analysed EOs contain mainly limonene, α-pinene, β-pinene, γ -terpinene, and linalyl acetate.</p>
      </list-item>
      <list-item>
       <p>
        <italic>C. aurantifolia</italic> inhibited more selectively AChE. The best activity was exerted by 
        <italic>C. aurantifolia</italic> and 
        <italic>C. aurantium</italic> that inhibited AChE of EOs with IC
        <sub>50</sub> values of 139.3 and 147.5 μg/mL, respectively.
       </p>
      </list-item>
      <list-item>
       <p>A lower bio-activity was observed against BChE with IC
        <sub>50</sub> values ranging from 235.5 to 266.6 μg/mL for 
        <italic>C. aurantifolia</italic> and 
        <italic>C. aurantium</italic>, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Obtained data suggest a potential use of citrus oils as a valuable new flavor with functional properties for food or nutraceutical products with particular relevance to supplements for the elderly.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">13.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cistus creticus</italic>
     <break/>
     <italic>Cistus salvifolius</italic>
     <break/>
     <italic>Cistus libanotis</italic>
     <break/>
     <italic>Cistus monspeliensis</italic>
     <break/>
     <italic>Cistus villo-sus</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B72-molecules-26-01107" ref-type="bibr">72</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>C. monspeliensis</italic> exhibited the most promising activity in β-carotene bleaching test (IC
        <sub>50</sub> of 54.7 μg/mL).
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>C. salvifolius</italic> showed the highest activity against AChE (IC
        <sub>50</sub> of 58.1 μg/mL) while 
        <italic>C. libanotis, C. creticus</italic> and 
        <italic>C. salvifolius</italic> demonstrated a good inhibitory activity against BChE with IC
        <sub>50</sub> values of 23.7, 29.1 and 34.2 μg/mL, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Not possible to clearly demonstrate the relationship between phytochemicals and bioactivity further studies must be conducted.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">14.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Clinopodium serpyllifolium (M.Bieb.) Kuntze</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B73-molecules-26-01107" ref-type="bibr">73</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—NA-FB)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The best AChE inhibitory activity was exhibited by the decoction extracts (IC
        <sub>50</sub> = 2.17–2.36 mg/mL), followed by the MeOH extracts (IC
        <sub>50</sub> = 3.03–3.12 mg/mL).
       </p>
      </list-item>
      <list-item>
       <p>The best BChE was exhibited by EO (IC
        <sub>50</sub> = 2.86–3.10 mg/mL), followed by the decoction (IC
        <sub>50</sub> = 3.31–3.87 mg/mL), and the MeOH extracts (IC
        <sub>50</sub> = 4.43–4.66 mg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>C. serpyllifolium</italic> could be a valuable natural source of antioxidants and cholinesterase inhibitors.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">15.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Daucus aristidis Coss.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B74-molecules-26-01107" ref-type="bibr">74</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The main components of 
        <italic>D. aristidis</italic> oils from Ghoufi were α-pinene (49–74.1%) and Bousaada were β-pinene (19.2–11.9%).
       </p>
      </list-item>
      <list-item>
       <p>The EO of 
        <italic>D. aristidis</italic> from Boussaada region displayed modest inhibition against AChE and BChE (61.75% and 56.79%, respectively).
       </p>
      </list-item>
      <list-item>
       <p>The aerial parts, stems, leaves and umbels of 
        <italic>D. aristidis</italic> EO from Ghoufi displayed low to moderate inhibition against AChE (51.0, 34.69, 13.44, and 33.07%, respectively) and BChE (41.46, 22.32, 23.70, and 30.00%, respectively).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EOs are complex mixtures of components that are usually more active than their isolated components. Their final activities are due to the combined effects of a number of minor components.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">16.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Hedychium gardnerianum</italic>,Sheppard ex Ker-Gawl
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B75-molecules-26-01107" ref-type="bibr">75</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>All the oils inhibited AChE, with IC
        <sub>50</sub> values of approximately 1 mg/mL.
       </p>
      </list-item>
      <list-item>
       <p>Three oils presented mixed inhibition, whilst one was almost truly competitive.This activity can be attributed to presence of sesquiterpenes, which constituted more than 60% of the composition of the oils.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Oils may contribute to the increase in acetylcholine in cholinergic neurons and to the fight against deleterious oxidation.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">17.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Hymenocrater bituminous</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B76-molecules-26-01107" ref-type="bibr">76</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GC–MS analysis of EO showed the presence of α-pinene (18.2%), β-pinene (11.3%), 
        <italic>trans</italic>-phytol (11.0%), and spathulenol (8.5%) as the major components
       </p>
      </list-item>
      <list-item>
       <p>EO showed high AChE (3.8 mg GEs/g oil) and BChE (4.7 mg GEs/g oil) inhibitory activities.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results indicated that 
        <italic>H. bituminous</italic> has promising potential for possible uses in food and pharmaceutical industries due to its valuable phytoconstituents and biological activities.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">18.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Illicium verum</italic> Hook.f
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B77-molecules-26-01107" ref-type="bibr">77</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>Bioautography method for detection of AChE and BchE inhibition</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Present study confirmed that anethole contributed to the anticholinesterase activity of 
        <italic>I. verum</italic>, with more specificity towards AChE.
       </p>
      </list-item>
      <list-item>
       <p>IC
        <sub>50</sub> for AChE and BChE inhibitory activity of anethole was 39.89 ± 0.32 μg/mL and 75.35 ± 1.47 μg/mL, whereas for the oil, 36.00 ± 0.44 μg/mL and 70.65 ± 0.96 μg/mL, respectively
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>I. verum</italic> fruit has potential inhibitory activity of AChE and BChE. This fruit and its oil could potentially lead to the development of anticholinesterase agents for the management of AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">19.</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula luisieri</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B78-molecules-26-01107" ref-type="bibr">78</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Inhibitory activity on Beta-site APP-cleaving enzyme 1 (BACE-1).</p>
      </list-item>
      <list-item>
       <p>Endogenous BACE-1 in cultured cells</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>High contents of oxygen-containing monoterpenes, mainly necrodane derivatives, which are absent from any other oil.</p>
      </list-item>
      <list-item>
       <p>EO from 
        <italic>L. luisieri</italic>, was signalised as inhibiting the BACE-1 enzyme.
       </p>
      </list-item>
      <list-item>
       <p>This oil was tested on the endogenous BACE-1 in cultured cells, being responsible for a reduction in Aβ production, with no significant toxicity.</p>
      </list-item>
      <list-item>
       <p>The main inhibitory activity was assigned to the monoterpenic ketone 2,3,4,4-tetramethyl-5-methylene-cyclopent-2-enone, one of the distinctive components of 
        <italic>L. luisieri</italic> EO.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This inhibitor could be used to study functional mechanisms of BACE-1 or other aspartic proteases in cells or animal models. It could contribute to the research of disorders related to deregulation of these proteins.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">20.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula angustifolia</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B24-molecules-26-01107" ref-type="bibr">24</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Thioflavin T measurement</p>
      </list-item>
      <list-item>
       <p>Atomic force microscope (AFM) Imaging</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The thioflavin T method showed that EO enhances the Aβ aggregation.</p>
      </list-item>
      <list-item>
       <p>The results of the AFM method also confirmed these effects.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Study suggests that combination of EOs (rose oil and lavender oil), vitamin C and Trolox with L-dopa can reduce oxidative toxicity, and may play a key role in ROS/reactive nitrogen species (RNS) disarming.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">21.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula pubescens</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B23-molecules-26-01107" ref-type="bibr">23</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EO composition revealed 25 constituents, of which carvacrol (65.27%) was the most abundant.</p>
      </list-item>
      <list-item>
       <p>EO exhibited strong antiAChE (IC
        <sub>50</sub> 0.9 μL/mL) and antiBChE (IC
        <sub>50</sub> 6.82 μL/mL) effects.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>LP EO makes a valuable natural source of bioactive molecules showing substantial potential as neuroprotective agents.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">22.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula viridis L’Her</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B79-molecules-26-01107" ref-type="bibr">79</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, Gas Chromatography–Ion Trap Mass Spectrometry (GC–ITMS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>Qualitative determination of false-positive effects in AChE andBChE inhibition assay—TLC</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Camphor was the main component identified in the EO (31.59 ± 1.32%), and in extracts from the first (1.61 ± 0.34%) and second supercritical fluid extraction (SFE) separators (22.48 ± 1.49%) at 12 MPa.</p>
      </list-item>
      <list-item>
       <p>The first separator SFE extract at 18 MPa was dominated by myrtenol (5.38 ± 2.04%) and camphor (4.81 ± 1.93%), second separator SFE extract was dominated by verbenone (13.97 ± 5.27%).</p>
      </list-item>
      <list-item>
       <p>Anti-cholinesterase activities EO was the most effective AChE inhibitor (IC
        <sub>50</sub> = 411.33 ± 72.73 μg/mL) than first separator SFE extracts.
       </p>
      </list-item>
      <list-item>
       <p>First separator SFE extracts were the most effective BChE inhibitors (IC
        <sub>50</sub> = 215.56 ± 13.60 and IC
        <sub>50</sub> = 204.76 ± 22.86 μg/mL at extraction pressures of 12 and 18 MPa). The second separator extracts did not achieve 50% inhibition at the highest final concentration (2.5 mg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Phytochemicals from the aerial parts of 
        <italic>L. viridis</italic> could be developed as natural antioxidant and anti-cholinesterase drugs, with particular applications in the symptomatic treatment of AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">23.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Mentha spicata L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B80-molecules-26-01107" ref-type="bibr">80</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay: AChE, BChE—New micro-well plate AChE activity (NA-FB) method</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical analysis of EO revealed 31 compounds with oxygenated monoterpenes (90%) as the most abundant components followed by sesquiterpene and monoterpene hydrocarbons (6% and 3%, respectively). 
        <italic>M spicata</italic> can be characterised as a carvone chemotype (65%).
       </p>
      </list-item>
      <list-item>
       <p>The EO of 
        <italic>M. spicata</italic> showed high levels of inhibitory activity against AChE and BChE inhibited cholinesterase enzymes in a concentration-dependent manner, with AChE (IC
        <sub>50</sub> = 23.1 μL/mL) and BuChE (IC
        <sub>50</sub> = 35.0 μL/mL) inhibitory activities
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The current study supports the utilisation of 
        <italic>M. spicata</italic> EO as a traditional medicine and opens perceptions to find more potent substances in the EO for the management of obesity, AD, and dermatophytosis and for combating drug-resistant bacterial infections.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">24.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Neomitranthes obscura</italic> (DC.) N. Silveira
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B81-molecules-26-01107" ref-type="bibr">81</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>17 compounds were identified, corresponding to 86.6% of the relative composition of this oil, being 3.9% of the oil constituted by monoterpenes and 82.7% constituted by sesquiterpenes.</p>
      </list-item>
      <list-item>
       <p>The major compounds found were 
        <italic>cis</italic>-nerolidol, 
        <italic>trans</italic>-nerolidol and β-bisabolene, corresponding to 19.3, 17.1, and 11.7% of relative composition, respectively.
       </p>
      </list-item>
      <list-item>
       <p>EO presented AChE inhibition with an IC
        <sub>50</sub> of 75.93 ± 0.85 μg/mL.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EO from species of “Restinga de Jurubatiba” National Park could be used as anticholinesterase inhibitors. Neomitranthes obscura remains unexplored regarding its biological properties.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">25.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Origanum rotundifolium Boiss.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B82-molecules-26-01107" ref-type="bibr">82</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major component was identified as carvacrol (56.8%) along with p-cymene (13.1%), (
        <italic>Z</italic>)-β-ocimene (5.4%), β-caryophyllene (3.9%), borneol (3.4%) and thymol (3.2%)
       </p>
      </list-item>
      <list-item>
       <p>Anticholinesterase activity against AChE with 38.66% inhibition, and BChE with 50.66% inhibition at 25 μg/mL concentration.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This is the first report on cholinesterase inhibitory activity of the EO of the plant.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">26.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Panax ginseng</italic>
     <break/>
     <italic>Panax japonicus</italic>
     <break/>
     <italic>P. notoginseng</italic>
     <break/>
     <italic>P. quinquefolius</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B83-molecules-26-01107" ref-type="bibr">83</xref>] 
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE)</p>
      </list-item>
      <list-item>
       <p>β-Secretase Inhibition</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spathulenol (8.82%), bicyclogermacrene (6.23%), β-elemene (3.94%), and α-humulene (3.69%) were identified as high content by GC–MS.</p>
      </list-item>
      <list-item>
       <p>EO (250 µg/mL) showed 41.4% inhibition against β-secretase, 77.4% inhibition against AChE, and 94.1% inhibition against BChE.</p>
      </list-item>
      <list-item>
       <p>Furthermore, β-elemene and α-humulene showed high activity among 3 compounds with 50% inhibitory concentration (IC
        <sub>50</sub>) values of 77.2 and 137.3 µM for AChE, and 298.2 and &gt;2000 µM for BChE, respectively.
       </p>
      </list-item>
      <list-item>
       <p>An EO extract of 
        <italic>P. japonicus</italic> showed the most potent activity with 51.3% inhibition at 500 μg/mL against β-secretase.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>P. ginseng</italic> showed the most potent inhibitory activity against AChE and BChE with 70.4% and 84.4% inhibition at 50 μg/mL, respectively.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>P. notoginseng</italic> extract showed the most potent activity with 57.3% inhibition at 500 μg/mL against Aβ aggregation.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>An EO extract of 
        <italic>P. ginseng</italic> could be an effective agent to improve AD symptoms.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">27.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Pinus sp.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B84-molecules-26-01107" ref-type="bibr">84</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Terpinolene, β-phellandrene, linalyl acetate, 
        <italic>trans</italic>-caryophyllene, and terpinen-4-ol were identified
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>P. heldreichii</italic> subsp. 
        <italic>leucodermis</italic> exhibited the most promising activity, with IC
        <sub>50</sub> values of 51.1 and 80.6 μg/mL against AChE and BChE, respectively.
       </p>
      </list-item>
      <list-item>
       <p>An activity against AChE was also observed with 
        <italic>P. nigra</italic> subsp. 
        <italic>nigra</italic> EO, with an IC
        <sub>50</sub> value of 94.4 μg/mL.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>Trans</italic>-caryophyllene and terpinen-4-ol inhibited BChE with IC
        <sub>50</sub> values of 78.6 and 107.6 μg/mL, respectively. β-Phellandrene was selective against AChE (IC
        <sub>50</sub> value of 120.2 μg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Results demonstrated that 
        <italic>Pinus</italic> EOs and some constituents have properties for the treatment of AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">28.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Piper divaricatum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B85-molecules-26-01107" ref-type="bibr">85</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—TLC)</p>
      </list-item>
      <list-item>
       <p>Molecular docking</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Methyl eugenol was the compound with the highest concentration ranging from 48.01% to 61.85%.</p>
      </list-item>
      <list-item>
       <p>The molecular docking revealed that β-elemene, eugenol, eugenyl acetate, and methyl eugenol are capable of interacting with different residues belonging to the active site of AChE, such as His447.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results of per-residue free energy decomposition demonstrated that the molecules, during the simulation, performed interactions with residues of the active site that are important for the enzymatic activity inhibition.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">29.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Polygonum hydropiper L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B22-molecules-26-01107" ref-type="bibr">22</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>141 and 122 compounds were identified in Ph.LO (leaf oils) and Ph.FO (flower oils), respectively.</p>
      </list-item>
      <list-item>
       <p>Caryophyllene oxide (41.42%) was the major component in Ph.FO while decahydronaphthalene (38.29%) was prominent in Ph.LO.</p>
      </list-item>
      <list-item>
       <p>In AChE inhibition, Ph.LO and Ph.FO exhibited 87.00 and 79.66% inhibitions at 1000 μg/mL with IC
        <sub>50</sub> of 120 and 220 μg/mL, respectively.
       </p>
      </list-item>
      <list-item>
       <p>The IC
        <sub>50</sub> value for galanthamine was 15 μg/mL. In BChE inhibitory assay, Ph.LO and Ph.FO caused 82.66 (IC
        <sub>50</sub> 130 μg/mL) and 77.50% (IC
        <sub>50</sub> 225 μg/mL) inhibitions, respectively, at 1000 μg/mL concentration.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Leaves and flowers of 
        <italic>P. hydropiper</italic> exhibited dose-dependent anticholinesterase and antioxidant activities.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">30.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Prangos gaubae</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B86-molecules-26-01107" ref-type="bibr">86</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EO analysis showed the presence of germacrene D (26.7%), caryophyllene oxide (14.3%), (
        <italic>E</italic>)-caryophyllene (13.8%), and spathulenol (11.3%) as the major volatile components.
       </p>
      </list-item>
      <list-item>
       <p>EO showed AChE (2.97 mg GEs/g oil) and BChE (3.30 mg GEs/g oil) inhibitory activities.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Results indicated that 
        <italic>P. gaubae</italic> has promising potential for possible uses in food, cosmetic, and pharmaceutical industries.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">31.</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Rumex hastatus</italic> D. Don
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B87-molecules-26-01107" ref-type="bibr">87</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The GC–MS analysis of EO showed 123 components.</p>
      </list-item>
      <list-item>
       <p>Anticholinesterase assays demonstrated a marked potential against AChE and BChE with IC
        <sub>50</sub> values of 32.54 and 97.38 μg/mL, respectively, which were comparable with the positive control, i.e., galantamine (AChE, IC
        <sub>50</sub> = 4.73 μg/mL and BChE, IC
        <sub>50</sub> = 11.09 μg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>R. hastatus</italic> is an effective source of EO components having anticholinesterase and antioxidant potential.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">32.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia officinalis</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B88-molecules-26-01107" ref-type="bibr">88</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>Anti-inflammatory activity (5-LOX inhibition assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Eighteen constituents were identified corresponding to 96.94% of present compounds.</p>
      </list-item>
      <list-item>
       <p>The main components were camphor (33.61%), 1,8-cineole (22.22%) and α-thujone (21.43%).</p>
      </list-item>
      <list-item>
       <p>EO inhibited the tested enzymes AChE (IC
        <sub>50</sub> = 8.71 ± 2.09 mg/L), 5-LOX (IC
        <sub>50</sub> = 36.15 ± 1.27 mg/L) and XOD (IP (%) = 36.89 ± 1.83 at a final concentration of 50 mg/L in the well.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>S. officinalis</italic> EO can be considered as a source of bioactive phytochemicals and phytotherapeutics for humans due to its anti-Alzheimer activities.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">33.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia chionantha</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B89-molecules-26-01107" ref-type="bibr">89</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Germacrene D (25.03%), β-caryophyllene (8.71%), spathulenol (5.86%) and α-humulene (4.82%) were identified as the major compounds.</p>
      </list-item>
      <list-item>
       <p>At 0.5 mg/mL concentration, the EO showed moderate AChE (56.7 ± 1.9%) and BChE (41.7 ± 2.9%) inhibitory activity.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The EO may be useful as a moderate anticholinesterase agent, particularly against AChE.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">34.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia chrysophylla Staph</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B90-molecules-26-01107" ref-type="bibr">90</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major components of the EO were α-terpinyl acetate (36.31%), β-caryophyllene (15.29%), linalool (8.12%) and β-elemene (4.26%).</p>
      </list-item>
      <list-item>
       <p>Anticholinesterase activity of the EO showed weak antioxidant activity. At 1 mg/mL concentration, the EO exhibited mild AChE (52.5 ± 2.0%) and moderate BChE (76.5 ± 2.7%) inhibitory activity.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Even if the EO demonstrated less AChE and BChE inhibitory activity than galantamine, it may be useful as a moderate BChE inhibitory agent. Some further studies should be done.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">35.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia urmiensis</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B20-molecules-26-01107" ref-type="bibr">20</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EO of leaves was rich in ester compounds such as ethyl linoleate (19%), methyl hexadecanoate (17%), and methyl linoleate (7.5%).</p>
      </list-item>
      <list-item>
       <p>The major compound of EO of flowers was 6,10,14-trimethyl-2-pentadecanone (55.7%).</p>
      </list-item>
      <list-item>
       <p>Exhibited moderate anticholinesterase activity (IC
        <sub>50</sub> = 44–892 µg/mL).
       </p>
      </list-item>
      <list-item>
       <p>EO-F showed the highest AChE and BChE inhibitory potential (IC
        <sub>50</sub> = 44 and 86 µg/mL, respectively) while EO-L showed inhibitory with IC
        <sub>50</sub> of 211 and 422 µg/mL, respectively
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results indicated that 
        <italic>S. urmiensis</italic> could be considered a valuable source for functional foods and pharmaceuticals.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">36.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia nemorosa L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B91-molecules-26-01107" ref-type="bibr">91</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Sixteen components were identified in the oil extracted from flowers (91.3% of the total oil) and 8 components were identified in the oil extracted from leaves (94.0% of the total oil).</p>
      </list-item>
      <list-item>
       <p>Obtained oils from leaves and flowers contain similar major compounds which are spathulenol (57.8 and 23.0%) and caryophyllene oxide (28.2 and 45.0%, respectively).</p>
      </list-item>
      <list-item>
       <p>EO-L and EO-F are also dominated by oxygenated sesquiterpenes (86 and 68%, respectively).</p>
      </list-item>
      <list-item>
       <p>EO from 
        <italic>S. nemorosa</italic> L.were generally less potent as an anti-AChE (IC 50 of EO-F: 488.9 ± 12.4 μg/mL and EO-L: 434.1 ± 11.6 μg/mL).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>S. nemorosa</italic> maybe useful for novel applications in functional food and pharmaceutical industries
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">37.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia officinalis L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B21-molecules-26-01107" ref-type="bibr">21</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (Fast GC–MS, Enantioselective GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>LOX inhibition assay</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The main components were α-thujone (22.8–41.7%), camphor (10.7–19.8%), 1,8-cineole (4.7–15.6%) and β-thujone (6.1–15.6%).</p>
      </list-item>
      <list-item>
       <p>Enantioselective gas chromatography identified (−)-α-thujone and (+)-camphor as the main enantiomers in all the analysed EOs.</p>
      </list-item>
      <list-item>
       <p>EO from 
        <italic>S. officinalis</italic> showed AChE inhibition with the following IC
        <sub>50</sub> values expressed in μg/mL: SoEO-3 (326.7 ± 24.8) ≤ SoEO-1 (338.1 ± 13.8) ≤ SoEO-4 (450.0 ± 25.6) &lt; SoEO-2 (867.4 ± 82.3).
       </p>
      </list-item>
      <list-item>
       <p>All four SoEO degrees of LOX inhibition (%) were as follows: SoEO-4 (52.8 ± 1.2) &gt; SoEO-2 (45.5 ± 1.5) ≥ SoEO-1 (44.3 ± 1.3) ≥ SoEO-3 (42.0 ± 0.9).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The characterisation carried out increases our awareness of the possible uses of 
        <italic>S. officinalis</italic> EO as natural additives in food, cosmetics and pharmaceuticals
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">38.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia syriaca L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B92-molecules-26-01107" ref-type="bibr">92</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GC–MS analysis showed that spathulenol (87.4%), isospathulenol (7.6%), and bornyl acetate (2.7%) are the major compounds in EO.</p>
      </list-item>
      <list-item>
       <p>HPLC analysis indicated that rutin, quercetin, apigenin, rosmarinic acid, and ferulic acid are the most abundant phenolic components.</p>
      </list-item>
      <list-item>
       <p>The enzyme inhibitory potential of the tested EO and extracts in comparison with galantamine were weak (EO, AChE: 1.9 ± 0.1 mg/mL, BChE: 3.06 ± 0.1 mg/mL).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>S. syriaca</italic> could be considered as a valuable source of bioactive natural compounds for functional foods, medical, and pharmaceutical applications.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">39.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Satureja thymbra L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B93-molecules-26-01107" ref-type="bibr">93</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Twenty-five compounds were identified by GC and GC–MS.</p>
      </list-item>
      <list-item>
       <p>The identified main compounds of the EO, carvacrol (34.6%), γ-terpinene (22.9%), p-cymene (13.0%) and thymol (12.8%) were also tested in the same manner.</p>
      </list-item>
      <list-item>
       <p>EO showed AChE (IC
        <sub>50</sub>: 150 ± 1.50 μg/mL) and BChE (IC
        <sub>50</sub>: 166 ± 2.00 μg/mL) inhibitory activities.
       </p>
      </list-item>
      <list-item>
       <p>The extract (IC
        <sub>50</sub>: 13.1 ± 0.23 μg/mL), the oil (IC
        <sub>50</sub>: 26.7 ± 0.56 μg/mL) and γ-terpinene (IC
        <sub>50</sub>: 11.9 ± 0.21 μg/mL) exhibited a good lipid peroxidation inhibitory activity.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Consumption of 
        <italic>S. thymbra</italic> may protect people against oxidative stress and amnesia without any side effect.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">40.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Stachys inflata,</italic>
     <break/>
     <italic>S. lavandulifolia,</italic>
     <break/>
     <italic>S. byzantina</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B94-molecules-26-01107" ref-type="bibr">94</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major volatile components of 
        <italic>S. inflata</italic> were identified as germacrene D (21.6%) and β-pinene (15.6%).
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>S. lavandulifolia</italic> contained mainly germacrene D (22.5%) and α-pinene (15.5%) whereas 
        <italic>S. byzantina</italic> showed hexahydrofarnesyl acetone (25.7%) and valeranone (17.1%) as major volatile constituents.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>S. inflata</italic> EO had the highest activity with 7.68 and 5.20 mg GALAEs/g EO, 
        <italic>S. byzantina</italic> EO were at the same level approximately at 6.62 and 5.06 mg GALAEs/g EO and 
        <italic>S. lavandulifolia</italic> EO showed remarkable activity at 4.96 and 4.88 mg GALAEs/g EO against BChE and AChE, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EOs of hedgenettle (betony) plants could be employed in the preparation of formulations to be used in cosmetics, food, and pharmaceutical products due totheir valuable antioxidant, neuroprotective, hypoglycemic, anti-obesity, and skin-care effects.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">41.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Sideritis galatica Bornm.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B95-molecules-26-01107" ref-type="bibr">95</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>23 components, representing 98.1% of 
        <italic>S. galatica</italic> EO (SGEO) were identified. Monoterpene hydrocarbons (74.1%), especially α- (23.0%) and β-pinene (32.2%), were the main constituents in SGEO.
       </p>
      </list-item>
      <list-item>
       <p>The main sesquiterpene hydrocarbons were β-caryophyllene (16.9%), germacrene-
        <sc>d</sc> (1.2%) and caryophyllene oxide (1.2%), respectively.
       </p>
      </list-item>
      <list-item>
       <p>The cholinesterase inhibitory activity of SGEO was very low when compared to galantamine. AChE (IC
        <sub>50</sub>: 0.618 mg/mL) and BChE (IC
        <sub>50</sub>: 0.632 mg/mL) inhibition ability of SGEO appear to be close.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This investigation suggests that SGEO can be considered as a source of natural agents for the development of new natural products such as food additives and drugs.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">42.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>S. ballsiana</italic>
     <break/>
     <italic>S. cyanescens</italic>
     <break/>
     <italic>S. divaricata</italic>
     <break/>
     <italic>S. hydrangea</italic>
     <break/>
     <italic>S. kronenburgii</italic>
     <break/>
     <italic>S. macrochlamys</italic>
     <break/>
     <italic>S. nydeggeri</italic>
     <break/>
     <italic>S. pachystachys</italic>
     <break/>
     <italic>S. pseudeuphratica</italic>
     <break/>
     <italic>S. rusellii</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B96-molecules-26-01107" ref-type="bibr">96</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC– MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>S. pseudeuphratica, S. hydrangea</italic> and 
        <italic>S. divaricata</italic> EOs demonstrated the most potent AChE inhibitory effect [50% inhibition concentration (IC
        <sub>50</sub>) = 26.00 ± 2.00 μg/mL, 40.0 ± 4.00, 64.68 ± 4.16, respectively].
       </p>
      </list-item>
      <list-item>
       <p>The EO of 
        <italic>S. pseudeuphratica</italic> demonstrated the highest inhibitory activity against AChE and BChE among the tested 
        <italic>Salvia</italic> EOs.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Evidences from the study augment the importance of EOs obtained from 
        <italic>Salvia</italic> sp. 
        <italic>Salvia</italic> sp. could be used to treat Alzheimer’s disease.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">43.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Thymus mastichina L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B97-molecules-26-01107" ref-type="bibr">97</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (fast GC–MS, enantioselective GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>5- LOX inhibition assay</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>1,8-Cineole and linalool were the main components, followed by α-pinene, β-pinene and α-terpineol. (–)-Linalool, (+)-α-terpineol and (+)-α-pinene were the most abundant enantiomers.</p>
      </list-item>
      <list-item>
       <p>All four 
        <italic>T. mastichina</italic> EO (α-pinene, β-pinene, limonene and 1,8-cineole) inhibited both lipoxygenase and AChE activities.1,8-cineole was the best AChE inhibitor with an IC
        <sub>50</sub> of 35.2 ± 1.5 μg/mL.
       </p>
      </list-item>
      <list-item>
       <p>Bornyl acetate and limonene showed the highest lipoxygenase inhibition and 1,8-cineole was the best AChE inhibitor.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These results support the potential applications of TmEO as natural ingredients in nutracosmeceutical products.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">44.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Thymus haussknechtii Velen.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B98-molecules-26-01107" ref-type="bibr">98</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The major component of the EO was thymol (52.2%).</p>
      </list-item>
      <list-item>
       <p>
        <italic>T. haussknechtii</italic> showed anticholinesterase activity against AChE with 57.33% and BChE with 40.11% inhibition at 25 μg/mL concentration.
       </p>
      </list-item>
      <list-item>
       <p>The EO obtained from 
        <italic>T. haussknechtii</italic> was rich in thymol (52.2%) and thymol exhibited strong acetyl- (83.0%) and BChE (98.0%) inhibitory activities.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These results indicate that 
        <italic>T. haussknechtii</italic> could be a good source for natural antioxidants which were very important in prevention of many disease and protection of health.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">45.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Thymus lotocephalus</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B99-molecules-26-01107" ref-type="bibr">99</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–IT-MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Linalool (10.43 ± 1.63%) was the main component in EO, whereas camphor (7.91 ± 0.84%) and 
        <italic>cis</italic>-linalool oxide (7.25 ± 1.45%) were the major compounds in the extracts; second separator obtained at pressures of 12 and 18 MPa, respectively.
       </p>
      </list-item>
      <list-item>
       <p>Caryophyllene oxide was the primary constituent identified in the extracts; first separator (4.34 ± 0.51 and 4.41 ± 1.25% obtained at 12 and 18 MPa, respectively).</p>
      </list-item>
      <list-item>
       <p>The inhibitory effect produced by the EO and extracts-1st separator were clearly more pronounced than that of the extracts; second separator, which did not reach 50% inhibition of either enzymes at the highest concentration tested (2.5 mg/mL).</p>
      </list-item>
      <list-item>
       <p>The EO was significantly (
        <italic>p</italic> &lt; 0.05) more active against BChE than AChE. Extraction pressure influenced the bioactivity of the SFE extract (first separator) isolated at the lowest pressure, which was the most active in inhibiting AChE (IC
        <sub>50</sub> = 1.54 ± 0.04 mg/mL). BChE activity at the similar pressure indicates IC
        <sub>50</sub> of 0.14 ± 0.02 mg/mL).
       </p>
      </list-item>
      <list-item>
       <p>BChE activity was more affected by EO than reference drug galanthamine, which was more active against AChE.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This research suggests 
        <italic>T. lotocephalus</italic> as a source of bioactive compounds with different targets and pathways.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">46.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Zingiber cassumunar</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B100-molecules-26-01107" ref-type="bibr">100</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>IC
        <sub>50</sub> values of native ZCEO show that it can be characterised as a moderate BChE inhibitor with IC
        <sub>50</sub> of 0.355 ± 0.137 mg/mL and a weak AChE inhibitor with IC
        <sub>50</sub> of 5.573 ± 0.176 mg/mL.
       </p>
      </list-item>
      <list-item>
       <p>Native ZCEO was formulated with microemulsion (ME) technique, and the suitable ZCEO ME was composed of Triton X-114 in combination with propylene glycol.</p>
      </list-item>
      <list-item>
       <p>The anticholinesterase activity of ME was higher than native ZCEO. It exhibited twenty times and twenty five times higher inhibitory activity against AChE (IC
        <sub>50</sub> = 0.252 ± 0.096 mg/mL) and BChE (IC
        <sub>50</sub> = 0.014 ± 0.002 mg/mL), respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>ZCEO loaded ME is an attractive formulation for further characterisation and an in vitro study in an animal model with AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">47.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Zosima absinthifolia Link</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B14-molecules-26-01107" ref-type="bibr">14</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>Anti-lipid peroxidation activity (TBA assay) Molecular docking</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The GC–FID and GC–MS analysis revealed that the main components of the aerial parts, roots, flowers and fruits extracts were octanol (8.8%), octyl octanoate (7.6%), octyl acetate (7.3%); 
        <italic>trans</italic>-pinocarvyl acetate (26.7%), β-pinene (8.9%); octyl acetate (19.9%), 
        <italic>trans</italic>-
        <italic>p</italic>-menth-2-en-1-ol (4.6%); octyl acetate (81.6%), and (
        <italic>Z</italic>)-4-octenyl acetate (5.1%).
       </p>
      </list-item>
      <list-item>
       <p>The dichloromethane fraction of fruit had the best inhibition against BChE enzyme (82.27 ± 1.97%) which was higher than AChE inhibition (61.09 ± 4.46%) of umbelliferone.</p>
      </list-item>
      <list-item>
       <p>The highest antioxidant potential in the TBA assay was seen in the fruit CH
        <sub>2</sub>Cl
        <sub>2</sub> fraction and flower EO (IC
        <sub>50</sub> = 48.98 and 97.11 g/mL, respectively).
       </p>
      </list-item>
      <list-item>
       <p>The fruit CH
        <sub>2</sub>Cl
        <sub>2</sub> fraction and flower EO indicated considerable inhibition against BChE (82.27 ± 1.97 and 78.65 ± 2.66%, respectively).
       </p>
      </list-item>
      <list-item>
       <p>The CH
        <sub>2</sub>Cl
        <sub>2</sub> fractions of root and fruit also showed considerable inhibition against AChE (29.15 ± 2.45 and 31.46 ± 2.78%).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Study shows that the flowers and fruit of 
        <italic>Z. absinthifolia</italic> can be a new potential resource of natural antioxidant and anticholinesterase compounds.
       </p>
      </list-item>
      <list-item>
       <p>Could be an herbal alternative to synthetic drugs in the prophylaxis of AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">48.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Calamintha nepeta</italic>, 
     <italic>Foeniculum vulgare</italic>, 
     <italic>Mentha spicata</italic> and 
     <italic>Thymus mastichina</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B101-molecules-26-01107" ref-type="bibr">101</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The main components of EOs were oxygenated monoterpenes, and aqueous extracts were rich in phenol and flavonoid compounds.</p>
      </list-item>
      <list-item>
       <p>EOs (0.5 mg/mL) showed high ability to inhibit cholinesterase activities, with IC
        <sub>50</sub> (concentration that inhibit 50% of enzyme activity) ranging from 0.08 to 0.24 and 0.09 to 0.23 mg/mL, for AChE and BChE, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EOs and aqueous extracts of 
        <italic>C. nepeta</italic>, 
        <italic>T. mastichina</italic>, 
        <italic>M. spicata</italic> and 
        <italic>F. vulgare</italic> from Alentejo region showed high antioxidant potential that may have an important role in the oxidative stress protection.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">49.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cymbopogon citratus</italic> (Gramineae), 
     <italic>Citrus hystrix</italic> (Rutaceae) and 
     <italic>Zingiber cassumunar</italic> (Zingiberaceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B102-molecules-26-01107" ref-type="bibr">102</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>C. citratus</italic> oil exhibited the highest activity with IC
        <sub>50</sub> values of 0.34 ± 0.07 µl/mL and 2.14 ± 0.18 µl/mL against BChE and AChE activity, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Citratus oil loaded microemusions are attractive systems for further in vivo studies in animal models with AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">50.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Alpinia galanga Linn., Centella asiatica Urban.,</italic>
     <break/>
     <italic>Cinnamomum bejolghota</italic> (Buch. Ham.) Sweet, 
     <italic>Citrus aurantifolia</italic> Swing, 
     <italic>Citrus hystrix DC.</italic>, 
     <italic>Citrus maxima (Burm.) Merr., Citrus reticulata Blanco cv. Shogun, Citrus reticulata var. Fremont, Cymbopogon citratus Stapf.</italic>, 
     <italic>Eupatorium odoratum Linn,. Melissa officinalis Linn., Ocimum basilicum Linn., Ocimum canum Sims., Ocimum gratissimum Linn., Ocimum sanctum Linn., Piper sarmentosum Roxb., Polygonum odoratum Lour., Polyscias fruticosa, Harms.Zingiber cassumunar Roxb,.</italic>
     <break/>
     <italic>Zingiber officinale Rosco</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B25-molecules-26-01107" ref-type="bibr">25</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GC–MS analysis revealed that the major constituents of 
        <italic>C. aurantifolia</italic> leaf oil are monoterpenoids including limonene, l-camphor, citronellol, o-cymene and 1,8-cineole.
       </p>
      </list-item>
      <list-item>
       <p>EOs obtained from 
        <italic>Melissa officinalis</italic> leaf and 
        <italic>Citrus aurantifolia</italic> leaf showed high AChE and BChE co-inhibitory activities.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>C. aurantifolia</italic> leaf oil revealed in this study had an IC
        <sub>50</sub> value on AChE and BChE of 139 ± 35 and 42 ± 5 μg/mL, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The excellent inhibitory activity of the EO of 
        <italic>C. aurantifolia</italic> on both enzymes suggests that this oil could be a promising substance for prevention and treatment of AD.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>C. aurantifolia</italic> is an attractive natural source to inhibit anticholinesterase and therefore warrants further study.
       </p>
      </list-item>
      <list-item>
       <p>The effect of combination of natural EOs would also be an interesting issue for further studies.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">51.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula angustifolia</italic>
     <break/>
     <italic>Coriandrum sativum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B103-molecules-26-01107" ref-type="bibr">103</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Assessment of cell viability by water-soluble tetrazolium salt (WST)-8</p>
      </list-item>
      <list-item>
       <p>Assessment of nuclear morphology</p>
      </list-item>
      <list-item>
       <p>Caspase-3 activity assay</p>
      </list-item>
      <list-item>
       <p>Assessment of intracellular reactive oxygen species (ROS) production</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Lavender and coriander EOs (10 μg/mL) as well as linalool at the same concentration were able to improve viability and to reduce nuclear morphological abnormalities in cells treated with Aβ1–42 oligomers for 24 h.</p>
      </list-item>
      <list-item>
       <p>Lavender, coriander EOs and linalool were also showed to counteract the increase in intracellular ROS production and the activation of the pro-apoptotic enzyme caspase-3 induced by Aβ1–42 oligomers.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This study suggests that EOs and their main constituent linalool could be natural agents of therapeutic interest.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">52.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Artemisia annua L.</italic> (Asteraceae)
     <break/>
     <italic>Glycyrrhiza glabra L.</italic> (Fabaceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B104-molecules-26-01107" ref-type="bibr">104</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Cholinesterase inhibition assay (AChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>1,8-cineole, carvacrol, myrtenal and verbenone apparently inhibited AChE; the highest inhibitory activity was observed for myrtenal (IC
        <sub>50</sub> = 0.17 mM).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This is the first report to show the potential of myrtenal present in the EO of 
        <italic>A. annua L.</italic> or 
        <italic>G. glabra L.</italic> as an AChE inhibitor.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">53.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Angelica sinensis</italic> (Oliv) Diels.
     <break/>
     <italic>Ligusticum Chuanxiong</italic> Hort
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B105-molecules-26-01107" ref-type="bibr">105</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Aβ25–35 and Aβ1–42 fibrils preparation</p>
      </list-item>
      <list-item>
       <p>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (SH-SY5Y and PC12 cells)</p>
      </list-item>
      <list-item>
       <p>Lactate dehydrogenase (LDH) release measurement</p>
      </list-item>
      <list-item>
       <p>Flow cytometric analysis</p>
      </list-item>
      <list-item>
       <p>Intracellular ROS measurement</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Z-ligustilide (Z-LIG) is an essential oil originally isolated from umbelliferous plants. Z-LIG at 1–30 mM provided an effective neuroprotection, as evidenced by the increase in cell viability, as well as the decrease in LDH release and intracellular accumulation of reactive oxygen species.</p>
      </list-item>
      <list-item>
       <p>Z-LIG markedly blocked Aβ fibril-induced condensed nuclei and sub-G1 accumulation suggestive of apoptosis.</p>
      </list-item>
      <list-item>
       <p>Furthermore, Z-LIG substantially reversed the activation of phosphorylated p38 and the inhibition of phosphorylated Akt caused by Aβ25–35.</p>
      </list-item>
      <list-item>
       <p>Z-LIG effectively protects against fibrillar aggregates of Aβ25–35 and Aβ1–42-induced toxicity in SH-SY5Y and differentiated PC12 cells, possibly through the concurrent activation of PI3-K/Akt pathway and inhibition of p38 pathway.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results taken together indicate that Z-LIG protects against Aβ fibrils-induced neurotoxicity possibly through the inhibition of p38 and activation of PI3-K/Akt signaling pathways concurrently. Z-LIG might be a potential candidate for further preclinical study aimed at the prevention and treatment of AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">54.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Achillea biebersteinii</italic> (Asteraceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B106-molecules-26-01107" ref-type="bibr">106</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Six groups of adult female Wistar rats (3 months old) were used. These are, control group, Sco-alone-treated group, diazepam alone-treated group, tramadol alone-treated group, Sco + 
        <italic>A. biebersteinii</italic> EO 1% administrated group and Sco + 
        <italic>A. biebersteinii</italic> EO 3% administrated groups.
       </p>
      </list-item>
      <list-item>
       <p>Memory performances were assessed by Y-maze task and radial-arm maze task. Anxiety and depressive-like behaviour were evaluated by elevated plus-maze and forced swimming tasks, respectively.</p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The scopolamine-only administered group showed impaired spatial memory as evidenced by a decrease in the spontaneous alternation percentage in the Y-maze test, and increase in the number of working and reference memory errors in the radial arm-maze test.</p>
      </list-item>
      <list-item>
       <p>In addition, scopolamine-only administered group displayed increased anxiety and depressive-like behaviour as evidenced by decrease in the exploratory activity, the percentage of the time spent and the number of entries in the open arm within elevated plus-maze test and decrease in swimming time and increase in immobility time within forced swimming test.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>A. biebersteinii</italic> EO significantly improved memory formation, and reduced anxiety and depression-like behaviour in scopolamine-induced rats as compared to scopolamine-alone induced rats. The EO of this plant could be a good candidate for complementary therapy against neurological diseases such as AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">55.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Boswellia serrata</italic>
     <break/>(Burseraceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B107-molecules-26-01107" ref-type="bibr">107</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Mice were administered the 42-amino acid form of amyloid β-peptide (Aβ1–42) to induce AD and then treated with olibanum EO (OEO) at 150, 300, and 600 mg/kg, for two weeks. Olibanum, the resin of the 
        <italic>B. serrata</italic>
       </p>
      </list-item>
      <list-item>
       <p>Following treatment, the AD mice were assessed by step-down test (SDT), dark avoidance test (DAT), and Morris water maze test (MWM). Blood and brain tissues were collected for biochemical assessments.</p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The main constituents of OEO were limonene, α-pinene, and 4-terpineol.</p>
      </list-item>
      <list-item>
       <p>Treatment with OEO prolonged t latency in SDT and DAT, but decreased error times.</p>
      </list-item>
      <list-item>
       <p>Escape latency decreased and crossing times rose in the MWM following OEO treatment (
        <italic>p</italic> &lt; 0.5). Treatment with OEO also enhanced the acetylcholine levels and decreased the AChE levels in serum and brain tissue (
        <italic>p</italic> &lt; 0.5).
       </p>
      </list-item>
      <list-item>
       <p>Additionally, OEO reduced amyloid plaques in the hippocampus and protected hippocampal neurons from damage. Furthermore, OEO decreased c-fos expression in hippocampus tissues from AD mice (
        <italic>p</italic> &lt; 0.5).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>OEO has a significant ameliorative effect AD-induced deterioration in learning and memory in AD mice. The mechanisms of these effects are related to the increase in acetylcholine.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">56.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Chamaecyparis obtuse</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B108-molecules-26-01107" ref-type="bibr">108</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>To model AD, 4 μg of aggregated Aβ was injected into the hippocampus. To test the effects of EO of 
        <italic>C. obtuse</italic> (EOCO), behavioural performance in the MWM was tested 4 days after injection. After behavioural testing, brain sections were prepared for 2,3,5-triphenyltetrazolium chloride (TTC) staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>AChE activity assays</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Inhaled EOCO protected spatial learning and memory from the impairments induced by Aβ1–40 injection. In addition, the behavioural deficits accompanying Aβ1–40-induced AD were attenuated by inhalation of EOCO.</p>
      </list-item>
      <list-item>
       <p>Furthermore, AChE activity and neuronal apoptosis were significantly inhibited in rats treated with Aβ1–40 and EOCO compared to rats treated only with Aβ1–40. AChE activity was significantly elevated (0.46 ± 0.05 U/mg protein, 
        <italic>p</italic> &lt; 0.001) and AChE content was decreased markedly (18.54 ± 1.17 umole/mg protein, 
        <italic>p</italic> &lt; 0.001) in the Aβ1–40 group.
       </p>
      </list-item>
      <list-item>
       <p>However, after treatment with donepezil or EOCO, AChE activity was significantly decreased and AChE content was significantly increased compared with the Aβ1–40 group. In addition, the EOCO group had less of a reduction in AChE activity than the donepezil group. The EOCO was composed of 45 main compounds with significant differences in the contributions of major monoterpenes (67.97%) and sesquiterpenes (25.97%).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EOCO suppressed both AD-related neuronal cell apoptosis and AD-related dysfunction of the memory system. Thus, the results of this study support EOCO as a candidate drug for the treatment of AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">57.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Citrus limon</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B109-molecules-26-01107" ref-type="bibr">109</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>APP/PS1 double transgenic AD mice</p>
      </list-item>
      <list-item>
       <p>The effects of lemon EO (LEO) on learning and memory were examined using the MWM test, novel object recognition test, and correlative indicators, including a neurotransmitter (AChE), a nerve growth factor (brain-derived neurotrophic factor, BDNF), a postsynaptic marker (PSD95), and presynaptic markers (synapsin-1, and synaptophysin), in APP/PS1 mice.</p>
      </list-item>
      <list-item>
       <p>Histopathology was performed to estimate the effects of LEO on AD mice.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>A significantly lowered brain AChE depression in APP/PS1 and wild-type C57BL/6L (WT) mice. PSD95/ Synaptophysin, the index of synaptic density, was noticeably improved in histopathologic changes.</p>
      </list-item>
      <list-item>
       <p>Hence, it can be summarised that memory-enhancing activity might be associated with a reduction in the AChE levels and is elevated by BDNF, PSD95, and synaptophysin through enhancing synaptic plasticity.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Offer in vivo evidence that LEO provides protection against AD-related synaptic loss and memory impairment. The finding also supports the importance of LEO as a “memory enhancer” in both the WT and APP/PS1 brain to mediate AChE, synaptic plasticity and cognitive function.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">58.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cymbopogon giganteus</italic>
     <break/>
     <italic>Illicium pachyphyllum</italic>
     <break/>
     <italic>Carum carvi</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B110-molecules-26-01107" ref-type="bibr">110</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Twenty-five rats were divided into five groups (/group): first group—control; second group— Aβ1–42 (1 mM) received donepezil treatment (5 mg/kg); third group— Aβ1–42 (1 mM); fourth and fifth groups—Aβ1–42 (1 mM) that received (−)-
        <italic>cis</italic>-carveol treatment groups (1% and 3%)
       </p>
      </list-item>
      <list-item>
       <p>Determination of the hippocampal AChE, SOD, CAT, Glutathione peroxidase (GPx) activity, Protein carbonyl and MDA level</p>
      </list-item>
      <list-item>
       <p>The total hippocampal content of reduced glutathione (GSH)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results of this study demonstrated that (−)-cis-carveol improved Aβ1–42-induced memory deficits examined by using Y-maze and radial arm maze in vivo tests.</p>
      </list-item>
      <list-item>
       <p>Additionally, the biochemical analyses of the hippocampus homogenates showed that (−)-
        <italic>cis</italic>-carveol reduced hippocampal oxidative stress caused by Aβ1–42.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The present work suggested that (−)-cis-carveol provides neuroprotection against Aβ1-42 and can be regarded as an alternative therapeutic agent for dementia-related neurological conditions, including AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">59.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Ferulago angulata</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B111-molecules-26-01107" ref-type="bibr">111</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>24 Male Wistar rats were divided into four groups: (1) Control group received 0.9% saline with 1% Tween 80 treatment; (2) Sco-alone received 0.9% saline with 1% Tween 80 treatment, as negative control; (3) Sco-treated received 
        <italic>F. angulata</italic> EO 1%; and (4) Sco-treated received 
        <italic>F. angulata</italic> EO 3%.
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–FID)</p>
      </list-item>
      <list-item>
       <p>Sco-induced memory impairments (Y-maze and radial arm-maze tasks).</p>
      </list-item>
      <list-item>
       <p>Decreased activities of superoxide dismutase, glutathione peroxidase and catalase; increase in AChE and decrease in total content of reduced glutathione</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Production of protein carbonyl and malondialdehyde significantly increased in the rat hippocampal homogenates of scopolamine-treated animals as compared with control, as a consequence of impaired antioxidant enzymes activities.</p>
      </list-item>
      <list-item>
       <p>Additionally, in scopolamine-treated rats exposure to 
        <italic>F. angulata</italic> EO significantly improved memory formation and decreased oxidative stress, suggesting memory-enhancing and antioxidant effects.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Our results suggest that multiple exposures to 
        <italic>F. angulata</italic> EO amelioratescopolamine-induced spatial memory impairment by attenuation of the oxidative stress in the rat hippocampus.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">60.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula angustifolia</italic> ssp. angustifolia Mill. (Lamiaceae)
     <break/>
     <italic>Lavandula hybrida</italic> Rev. (Lamiaceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B112-molecules-26-01107" ref-type="bibr">112</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>50 male Wistar rats were divided into 5 groups: (1) Control received saline treatment (0.9% NaCl); (2) Sco-treated received silexan, as + control; (3) Sco alone-treated; (4) Sco-treated received 
        <italic>Lavandula angustifolia</italic> EO (LO1 + Sco); and (5) Sco-treated received 
        <italic>Lavandula hybrida</italic> EO (LO2 + Sco).
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Behavioural recovery (maze task, forced swimming test) following chronic exposure to the extracted EO using sco-induced dementia rat model, are investigated.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The main components in both analysed samples, LO1 and LO2, were linalool (28.0% and 21.5%, respectively) and linalyl acetate (17%, 22.5%, respectively) followed by terpinen-4-ol (3.3% and 16.7%), lavandulyl acetate (8.3% and 8.4%). Interesting is that the presence of camphor and borneol was in trace amounts.</p>
      </list-item>
      <list-item>
       <p>Chronic exposures to lavender EOs (daily, for 7 continuous days) significantly reduced anxiety-like behaviour and inhibited depression in elevated plus-maze and forced swimming tests, suggesting anxiolytic and antidepressant activity.</p>
      </list-item>
      <list-item>
       <p>Additionally, spatial memory performance in Y-maze and radial arm-maze tasks was improved, suggesting positive effects on memory formation.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Multiple exposures to lavender EOs could effectively reverse spatial memory deficits in the rat brain and might provide an opportunity for management neurological abnormalities in dementia conditions.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">61.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Ocimum basilicum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B113-molecules-26-01107" ref-type="bibr">113</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Forty male Swiss albino mice divided into four groups (
        <italic>n</italic> = 10); the control, chronic unpredictable mild stress (CUMS), CUMS + Fluoxetine, CUMS + OB were used.
       </p>
      </list-item>
      <list-item>
       <p>Behavioural tests, serum corticosterone level, hippocampus protein level of the glucocorticoid receptors (GRs) and brain derived neurotropic factor (BDNF) were determined after exposure to CUMS. Hippocampus was histopathologically examined.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>O. basilicum</italic> diminished the depression manifestation as well as impaired short term memory observed in the mice after exposure to the CUMS as evidenced by the forced swimming and elevated plus maze test.
       </p>
      </list-item>
      <list-item>
       <p>
        <italic>O. basilicum</italic> also up-regulated the serum corticosterone level, hippocampal protein level of the glucocorticoid receptor and the brain-derived neurotropic factor and reduced the neurodegenerative and atrophic changes induced in the hippocampus after exposure to CUMS.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EO of 
        <italic>O. basilicum</italic> alleviated the memory impairment and hippocampal neurodegenerative changes induced by exposure to the chronic unpredictable stress indicating that it is the time to test its effectiveness on patients suffering from Alzheimer’s disease.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">62.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Ocimum sanctum L.</italic>
     <break/>
     <italic>Ocimum basilicum L.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B114-molecules-26-01107" ref-type="bibr">114</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>80 male Wistar rats (3 were divided into 8 groups: (1) Control received saline treatment (0.9% NaCl); (2) Diazepam alone-treated (DZP, 1.5 mg/kg); (3) Tramadol alone-treated (TRM, 10 mg/kg); (4) Aβ1–42 alone-treated; (5) Aβ1-42-treated received 
        <italic>O. sanctum</italic> oil 1%; (6) Aβ1–42-treated received O. sanctum oil 3%; (7) Aβ1–42-treated received 
        <italic>O. basilicum</italic> oil 1%; and (8) Aβ1–42-treated received 
        <italic>O. basilicum</italic> oil 3%. Control, DZP, TRM and Aβ1-42 alone-treated groups were caged in the same conditions but in the absence of the tested oils.
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>The anxiolytic- and antidepressant-like effects of inhaled basil EOs were studied by means of in vivo (elevated plus-maze and forced swimming tests) approaches.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The Aβ1–42-treated rats exhibited the following: decrease in the exploratory activity (number of crossing), the percentage of the time spent and the number of entries in the open arm within elevated plus-maze test and increase in the swimming time and decrease in the immobility time within forced swimming test.</p>
      </list-item>
      <list-item>
       <p>The main compounds found in both samples were linalool (31% Ob, 19% Os), camphor, β-elemene, α-bergamotene and bornyl-acetate, estragole (15.57 and 7.59%, respectively), eugenol (2.64 and 1.39%, respectively) and 1,8-cineole (3.29 and 3.90%, respectively).</p>
      </list-item>
      <list-item>
       <p>The exposure to basil EOs significantly improved the behaviour of the animals, suggesting anxiolytic- and antidepressant-like effects.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Multiple exposures to basil EOs can be useful to counteract anxiety and depression in AD conditions. Future perspectives of this study include a rather new cultivar of basil (
        <italic>O. basilicum</italic> var. 
        <italic>purpurascens</italic>).
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">63.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Pimpinella peregrina</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B115-molecules-26-01107" ref-type="bibr">115</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Y-maze and radial arm-maze tests were used for assessing memory processes. Additionally, the anxiety and depressive responses were studied by means of the elevated plus-maze and forced swimming tests</p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The scopolamine alone-treated rats exhibited the following: decrease in the spontaneous alternation percentage in Y-maze test, increase in the number of working and reference memory errors in radial arm-maze test, along with decrease in the exploratory activity, the percentage of the time spent and the number of entries in the open arm within elevated plus-maze test and decrease in swimming time and increase in immobility time within forced swimming test.</p>
      </list-item>
      <list-item>
       <p>Inhalation of the 
        <italic>P. peregrina</italic> EO significantly improved memory formation and exhibited anxiolytic- and antidepressant-like effects in scopolamine-treated rats.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Results suggest that the 
        <italic>P. peregrina</italic> EO inhalation ameliorates scopolamine-induced memory impairment, anxiety, and depression. studies on the 
        <italic>P. peregrina</italic> EO may open a new therapeutic window for the prevention of neurological abnormalities closely related to AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">64.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Pinus halepensis</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B116-molecules-26-01107" ref-type="bibr">116</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Rats were behaviourally tested (radial arm maze and Y-maze activities used). Rats were divided into five groups: first group—vehicle, second group—Aβ1–42, the third and fourth group—
        <italic>P. halepensis</italic> EO (PNO) treatment groups (1% and 3%), and fifth group—donepezil group (as positive control, 5 mg/kg injected in Aβ1–42-treated rats). Additionally, biochemical estimations of the brain homogenates for AChE and oxidative stress biomarkers were carried out.
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Determination of hippocampal AChE, SOD, CAT, GPX activity</p>
      </list-item>
      <list-item>
       <p>Determination of hippocampal protein carbonyl and MDA level</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The EO reversed the Aβ1–42-induced decreasing of the spontaneous alternation in the Y-maze test and the Aβ1–42-induced increasing of the working and reference memory errors in the radial arm maze test.</p>
      </list-item>
      <list-item>
       <p>The Aβ1–42-induced modification of the balance oxidant-antioxidant and AChE action in the hippocampus of the rat has been ameliorated using the EO.</p>
      </list-item>
      <list-item>
       <p>Most of the volatile components belong to the sesquiterpene group (54.14%), and monoterpenes represent the rest of them, and only 2.50% are diterpenes (mainly cembrene).</p>
      </list-item>
      <list-item>
       <p>Aβ1–42 administration resulted in a substantial increase in the hippocampus AChE action (
        <italic>p</italic> &lt; 0.0001) in comparison with the vehicle group. PNO (1% and 3%) treated groups significantly decreased the elevated AChE action (
        <italic>p</italic> &lt; 0.0001 for PNO1% and 
        <italic>p</italic> &lt; 0.0001 for PNO3%) as compared to Aβ1–42 rats.
       </p>
      </list-item>
      <list-item>
       <p>In comparison with the vehicle group, injection of the Aβ1–42 resulted in significant decrease in SOD (
        <italic>p</italic> &lt; 0.0001), CAT (
        <italic>p</italic> &lt; 0.0001), and GPX (
        <italic>p</italic> &lt; 0.0001). GSH levels were decreased after Aβ1–42 treatment (
        <italic>p</italic> &lt; 0.0001), while elevated protein carbonyl (
        <italic>p</italic> &lt; 0.0001) and MDA (
        <italic>p</italic> &lt; 0.0001) levels were noticed as compared to vehicle groups.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>P. halepensis</italic> EO may be regarded as a therapeutic tool for attenuation of Aβ toxicity and neuronal dysfunction.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">65.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Kushui rose (Rosa setate × Rosa rugosa)</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B117-molecules-26-01107" ref-type="bibr">117</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Paralysis assay, Fluorescence staining of Aβ deposits assay, Exogenous rerotonin sensitivity assay, RNA interference (RNAi) assay, Subcellular DAF-16 or skinhead-1 (SKN-1) nuclear localisation assay, The gst-4::gfp expression assay, Western blotting</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Rose EO (REO) significantly inhibited AD-like symptoms of worm paralysis and hypersensitivity to exogenous 5-HT in a dose-dependent manner.</p>
      </list-item>
      <list-item>
       <p>Its main components of β-citronellol and geraniol acted less effectively than the oil itself.</p>
      </list-item>
      <list-item>
       <p>REO significantly suppressed Aβ deposits and reduced the Aβ oligomers to alleviate the toxicity induced by Aβ overexpression. Additionally, the inhibitory effects of REO on worm paralysis phenotype were abrogated only after skn-1 RNAi but not daf-16 and hsf-1 RNAi.</p>
      </list-item>
      <list-item>
       <p>REO markedly activated the expression of gst-4 gene, which further supported SKN-1 signaling pathway was involved in the therapeutic effect of REO on AD 
        <italic>C. elegans.</italic>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Our results provided direct evidence on REO for treating AD on an organism level and relative theoretical foundation for reshaping medicinal products of REO in the future.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">66.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Rosmarinus officinalis</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B118-molecules-26-01107" ref-type="bibr">118</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Mice were administered Rosemary EO (EORO) by inhalation. Then, scopolamine was used to prepare Alzheimer’s type dementia model mice. To evaluate cognitive function, the Y-maze test was used for assessment of short-term memory.</p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EORO produced a significant improvement in the rate of spontaneous alternation behaviour.</p>
      </list-item>
      <list-item>
       <p>Furthermore, 1,8-cineole, α-pinene, and β-pinene, the main components of EORO, were detected in the brain in a concentration-dependent manner following inhalation of EORO.</p>
      </list-item>
      <list-item>
       <p>Components such as 1,8-cineole and others are likely involved in the effects on the brain.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The effect of improving cognitive function by inhaled administration of EORO, which has been used empirically, was clarified for the first time.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">67.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia miltiorrhiza Bge</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B119-molecules-26-01107" ref-type="bibr">119</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>The AD mice model was induced by D-gal plus AlCl
        <sub>3</sub>, and then the mice in the experimental group were treated with EO from aerial parts of 
        <italic>S. miltiorrhiza</italic>.
       </p>
      </list-item>
      <list-item>
       <p>The protective effects of EO on the memory impairment of mice were determined by the MWM test.</p>
      </list-item>
      <list-item>
       <p>Biochemical determinations: superoxide dismutase (SOD), catalase (CAT), (MDA), AChE kits were used).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Terpenoids was the main components of EO from aerial parts of 
        <italic>S. miltiorrhiza</italic>, accounting for about 50.18% of the total EO, and β-caryophyllene (8.58%), 6,10,14-trimethyl-2-pentadecanone (7.97%), dihydro-neoprene (7.96%), germacrene D (6.37%) caryop, hyllene (4.22%) were the main and characteristic compositions of the EO.
       </p>
      </list-item>
      <list-item>
       <p>The EO, given orally, prevented cognitive impairment in AD mice induced by D-gal plus AlCl
        <sub>3</sub>. Compared to the model group, SOD activity, CAT activity and Ach content were found to be increased in test group mice, while AchE activity and MDA content were decreased.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>All the above suggest that EO from aerial parts of 
        <italic>S. miltiorrhiza</italic> improves AD-like symptoms in mice induced by 
        <sc>d</sc>-gal and AlCl
        <sub>3</sub>, and has the potential to develop a new drug for the treatment of AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">68.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Schisandra chinensis</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B120-molecules-26-01107" ref-type="bibr">120</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Male KM mice weighing 20–25 g.</p>
      </list-item>
      <list-item>
       <p>Behaviour tests include open-field behaviour, Y-maze and MWM tests.</p>
      </list-item>
      <list-item>
       <p>Biochemical analysis include Western blot, Enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining and histology assay.</p>
      </list-item>
      <list-item>
       <p>Cell viability assay and cytotoxicity (MTT assay) of 
        <italic>S. chinensis</italic> EO (SEO) are also evaluated along with measurement of nitric oxide level.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>SEO improved the cognitive ability of mice with Aβ1-42 or LPS-induced AD and suppressed the production of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the hippocampus.</p>
      </list-item>
      <list-item>
       <p>Furthermore, SEO inhibited p38 activation, but had little effect on other signaling proteins in the MAPK family, such as extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase 1/2 (JNK). The SEO and BV-2 microglia co-culture was performed to further confirm the anti-inflammatory activity of SEO.</p>
      </list-item>
      <list-item>
       <p>The data showed that SEO decreased nitric oxide (NO) levels in LPS-stimulated BV-2 microglia and significantly blocked LPS-induced MAPKs activation.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Study suggests that SEO produces anti-AD effects on AD mice by modulating neuroinflammation through the NF-κB/MAPK signaling pathway.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">69.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">SuHeXiang Wan (SHXW)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B121-molecules-26-01107" ref-type="bibr">121</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>We evaluated the effects of a modified SHXW (called KSOP1009) intake on the AD-like phenotypes of Drosophila AD models, which express human Aβ1–42 in their developing eyes or neurons.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>When the flies were kept on the media containing 5 μg/mL of KSOP1009 extract, Aβ1–42-induced eye degeneration, apoptosis, and the locomotive dysfunctions were strongly suppressed. However, Aβ1–42 fibril deposits in the Aβ1-42 overexpressing model were not affected by treatment with KSOP1009 extract. Conversely, KSOP1009 extract intake significantly suppressed the constitutive active form of hemipterous, a JNK activator, while it induced eye degeneration and JNK activation.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Study suggests KSOP1009 confers a therapeutic potential to AD-like pathology of Aβ1-42 overexpressing Drosophila model.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">70.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Tetraclinis articulata</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B122-molecules-26-01107" ref-type="bibr">122</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>
        <italic>T. articulata</italic> EO was administered by inhalation to male Wistar rats once daily for 15 min period at doses of 1% and 3% for 21 days after the intracerebroventricular administration of Aβ1–42 right-unilaterally to induce memory deficits. Spatial memory of rats was tested using Y-maze and radial arm maze tests.
       </p>
      </list-item>
      <list-item>
       <p>In vivo brain antioxidant and AChE inhibitory effect.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The GC–MS and GC–FID data showed that the EO has a high percent of monoterpene hydro-carbons.</p>
      </list-item>
      <list-item>
       <p>EO reversed the Aβ1–42-induced decreasing of the spontaneous alternation in the Y-maze test and the Aβ1–42-induced increasing of the working and reference memory errors in the radial arm maze test. Furthermore, the Aβ1–42-decreased the AChE activity and the oxidant-antioxidant status in the rat hippocampus was retrieved by the treatment with the EO.</p>
      </list-item>
      <list-item>
       <p>AChE activity in the hippocampal tissues of Aβ1–42 group was higher as compared to control group (
        <italic>p</italic> &lt; 0.01), while treatment by EO decreased AChE activity in the hippocampus as compared to Aβ1–42 group (
        <italic>p</italic> &lt; 0.0001 for TLO1% and 
        <italic>p</italic> &lt; 0.001 for TLO3%). Thus, TLO reduced the cholinergic deficits produced after Aβ1–42 administration resulting in enhanced nootropic effect in the Y-maze and radial arm maze tests.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The study demonstrates that the EO could be a potent pharmacological agent against dementia by modulating cholinergic activity and promoting antioxidant action in the rat hippocampus.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">71.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Zataria multiflora Boiss.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B123-molecules-26-01107" ref-type="bibr">123</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Forty male adult rats were categorised into four groups and treated as follows: 1. Negative Control (NC): no treatment; 2. Sham control (sham): distilled water by Intracerebroventricular (ICV) injection; 3. The AD control (AD): Aβ1–42 by ICV injection; and 4. The 
        <italic>Z. multiflora</italic> EO (ZMEO) group: Aβ1–42 by ICV injection and ZMEO at 100 μL/kg/d orally for 20 days.
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>AChE activity assay.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>After Congo red staining of the hippocampus, a relative decrease in amyloid deposits was observed in the ZMEO group. Moreover, rats showed better outcomes in MWM test, reduced hippocampal AChE activity, and higher BDNF content as compared with the AD group (
        <italic>p</italic> &lt; 0.05). However, no significant changes in antioxidant status was observed (
        <italic>p</italic> &gt; 0.05).
       </p>
      </list-item>
      <list-item>
       <p>Thymol and carvacrol were the major constituents each comprising more than 30% of the EO, followed by p-cymene with 9.5%.</p>
      </list-item>
      <list-item>
       <p>The AChE enzyme activity significantly increased in the AD group as compared with the NC or sham groups (
        <italic>p</italic> &lt; 0.001). Rats in the ZMEO group showed a significantly decreased activity of the enzyme in hippocampal tissue as compared with the AD group (
        <italic>p</italic> &lt; 0.001). Interestingly, no significant difference was observed between the ZMEO, and NC or sham groups (
        <italic>p</italic> &gt; 0.05).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>ZMEO improves spatial learning and memory of rats with AD as assessed by MWM test. These effects are associated with decreased concentrations of hippocampal tau protein and TNF-α.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">72.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Z. multiflora Boiss.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B124-molecules-26-01107" ref-type="bibr">124</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Thirty-five adult male Sprague Dawley rats were randomly divided into 5 groups control (intact rats); sham (normal saline); AD control; vehicle control (rats with AD that orally received tween 80, 5% (ZMEO vehicle) for 20 days) and experimental (rats with AD that orally received ZMEO 100 µl/kg/day for 20 days). AD was induced by bidirectional microinjection of Aβ1–42.</p>
      </list-item>
      <list-item>
       <p>Tau protein and TNF-α concentrations were measured by ELISA methods.</p>
      </list-item>
      <list-item>
       <p>Spatial cognitive and noncognitive behaviour were determined by the MWM test.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>ZMEO significantly improved latency time, time spent in the target quarter and cognitive behaviour of rats with AD compared to control and sham groups (
        <italic>p</italic> &lt; 0.05). Hippocampal tau protein and TNF-α concentrations were significantly higher in both AD control and vehicle groups compared to control and sham groups, respectively (
        <italic>p</italic> &lt; 0.01 and 
        <italic>p</italic> &lt; 0.001), administration of ZMEO reduced these parameters as compared to AD control and vehicle groups, respectively (
        <italic>p</italic> &lt; 0.01 and 
        <italic>p</italic> &lt; 0.001).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>ZMEO improves spatial learning and memory of rats with AD as assessed by MWM test. These effects are associated with decreased concentrations of hippocampal tau protein and TNF-α.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">73.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Origanum vulgare</italic>
     <break/>
     <italic>Thymus vulgaris</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B125-molecules-26-01107" ref-type="bibr">125</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Forty male albino rats divided into four groups as follows: control, AlCl
        <sub>3</sub> induced AD, carvacrol oil treated and carvacrol nanoemulsion treated groups.
       </p>
      </list-item>
      <list-item>
       <p>Brain nor-epinephrine, serotonin and dopamine were analysed by HPLC.</p>
      </list-item>
      <list-item>
       <p>Levels of brain thiobarbituric acid-reactive substances (TBARS), SOD, GSH, cholinesterase, and advanced oxidation protein product (AOPP) were evaluated. Urinary 8-hydroxyguanosine (8-OHdG) level was evaluated by HPLC.</p>
      </list-item>
      <list-item>
       <p>Brain cyclooxygenase 1 and 2 (COX 1 and 2) were analysed by immunohistochemistry.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>AD induced by AlCl
        <sub>3</sub> in rats was depicted by the significant increase in the neurotransmitters levels which is accompanied with high degree of oxidative stress that was revealed in the elevated level of urinary 8-OHdG along with significant elevation in AOPP, TBARS, and cholinesterase levels and a significant decrease in SOD and GSH; these results are confirmed by immunohistochemistry analysis of COX 1 and 2.
       </p>
      </list-item>
      <list-item>
       <p>Treatment with carvacrol oil and carvacrol nanoemulsion were capable of mitigating effects mediated by AlCl
        <sub>3</sub> administration in treated rats. While the treatment with both approaches succeeded to retract the negative impact of AlCl
        <sub>3</sub>; but the effect of carvacrol nanoemulsion was more notable than the EO. Carvacrol oil and carvacrol nanoemulsion were eminent to overturn AlCl
        <sub>3</sub> induced brain AD which could be imputed to antioxidant and anti-inflammatory capabilities of carvacrol to alter oxidative stress effect. In extension; carvacrol nanoemulsion was evident to give a more effective and efficient way in carvacrol delivery to pass through blood–brain barriers and ameliorate brain changes.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Carvacrol nanoemulsion as a possible treatment for AD symptoms and its biochemical changes inside the brain is a new successful approach that combine between both.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">74.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Acori graminei</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B126-molecules-26-01107" ref-type="bibr">126</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Using PC12 cells and primary cultures of cortical neurons treated with Aβ1–40 or Aβ1–42 peptide. AβPP/PS1 mice at the age of 3 months and age-matched wild-type mice were intragastrically administered β-asarone (7 mg/kg/day, 21 mg/kg/day) or a vehicle daily for 4 months.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>β-asarone can protect PC12 cells and cortical neurons and inhibit neuronal apoptosis by activating the CaMKII-α/p-CREB/Bcl-2 pathway.</p>
      </list-item>
      <list-item>
       <p>CaMKII-α overexpression enhanced the β-asarone-induced p-CREB-Bcl-2 expression and anti-apoptotic effects. Interestingly, suppression of CaMKII-α by siRNA or a specific inhibitor can significantly reduce the β-asarone-induced p-CREB and Bcl-2 expression and Aβ1–40 induced neuronal apoptosis in PC12 cells. β-asarone improved cognitive function of the AβPP/PS1 mice and reduced neuronal apoptosis in the cortex of the AβPP/PS1 mice. A significant increase in CaMKII/CREB/Bcl-2 expression was observed in the cortex of the AβPP/PS1 mice treated with β-asarone.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>β-asarone can inhibit neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in in vitro models and in AβPP/PS1 mice. Therefore, β-asarone can be used as a potential therapeutic agent in the long-term treatment of AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">75.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Foeniculi vulgare aetheroleum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B127-molecules-26-01107" ref-type="bibr">127</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>Inhibition of 15-LOX</p>
      </list-item>
      <list-item>
       <p>Elevated plus-maze and forced swimming tests</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>trans</italic>-Anethole (58.1%), a phenylpropanoid, was found as the main component. Camphor (21.3%), a terpene ketone, was the second major compound detected in fennel EO, followed by carvone (7.8%), 
        <italic>trans</italic>-sabinene hydrate (3.1%), β-pinene (2.6%), and others were found to be the minor components in the EO of fennel seeds.
       </p>
      </list-item>
      <list-item>
       <p>The Aβ1–42-treated rats exhibited the following: decrease in the exploratory activity, the percentage of the time spent and the number of entries in the open arm within elevated plus-maze test and decrease in swimming time and increase in immobility time within forced swimming test. Inhalation of the fennel EO significantly exhibited anxiolytic- and antidepressant-like effects. Our results suggest that the fennel EO inhalation ameliorates Aβ1–42-induced anxiety and depression in laboratory rats.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results of the present study indicate that the fennel EO may have potential clinical applications in the management of anxiety and depression related to AD conditions.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">76.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula angustifolia Mill.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B128-molecules-26-01107" ref-type="bibr">128</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Cognitive deficits were induced in C57BL/6J mice treated with sco (1 mg/kg, i.p.) and were assessed by MWM and step-through passive avoidance tests.</p>
      </list-item>
      <list-item>
       <p>Biochemical assays (AChE), SOD, GPx and MDA.</p>
      </list-item>
      <list-item>
       <p>In vitro, the cytotoxicity were induced by 4 h exposure to H
        <sub>2</sub>O
        <sub>2</sub> in PC12 and evaluated by cell viability (MTT), lactate dehydrogenase (LDH) level, nitric oxide (NO) release, ROS) production and mitochondrial membrane potential (MMP).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>LO (100 mg/kg) could improve the cognitive performance of scopolamine induced mice in behavioural tests. Meanwhile, it significantly decreased the AChE activity, MDA level, and increased SOD and GPx activities of the model. Moreover, LO (12 μg/mL) protected PC12 cells from H
        <sub>2</sub>O
        <sub>2</sub>-induced cytotoxicity by reducing LDH, NO release, intracellular ROS accumulation and MMP loss. AChE activity in the hippocampus of the model group was increased significantly compared with that of control mice (
        <italic>p</italic> &lt; 0.05). The LO (100 mg/kg) and donepezil decreased the AChE activity in scopolamine treated mice (
        <italic>p</italic> &lt; 0.05). Similarly, with the treatment of LO (100 mg/kg) and donepezil, significant attenuation of MDA level increase was observed in scopolamine treated mice (
        <italic>p</italic> &lt; 0.05).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>It was suggested that LO could show neuroprotective effect in AD model in vitro. LO may be a potential drug for the treatment of cognitive.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">77.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula angustifolia Mill.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B129-molecules-26-01107" ref-type="bibr">129</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>A total of 90 male C57BL/6J mice (12 weeks) were randomly divided into 6 groups, control (given vehicle), AD group (given vehicle), lavender EO (LO) + AD groups (50, 100 mg/kg/d), and linalool + AD groups (50, 100 mg/kg/d).</p>
      </list-item>
      <list-item>
       <p>Behavioural tests were performed using open-field test (OFT), MWM and passive avoidance task (PAT).</p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>AChE activity in the hippocampus and cortex were measured according to the protocol of assay kit</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>LO and linalool significantly protected the decreased activity of SOD, GPX, and protected the increased activity of AChE and content of MDA. Besides, they protected the suppressed nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression significantly. Moreover, the decreased expression of synapse plasticity-related proteins, calcium-calmodulin-dependent protein kinase II (CaMKII), p-CaMKII, BDNF, and TrkB in the hippocampus were increased with drug treatment. AChE activity in the hippocampus and cortex of the D-gal and AlCl
        <sub>3</sub> group was increased significantly compared with that of the control group. The LO (100 mg/kg) and LI (100 mg/kg) protected the activity of AChE in the cortex of model mice markedly. Besides, linalool (100 mg/kg) also significantly reversed the D-gal and AlCl
        <sub>3</sub>-induced AChE activity increase in the hippocampus.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>LO and its active component linalool have protected the oxidative stress, activity of cholinergic function and expression of proteins of Nrf2/HO-1 pathway, and synaptic plasticity. It suggests that LO, especially linalool, could be a potential agent for improving cognitive impairment in AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">78.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula luisieri</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B130-molecules-26-01107" ref-type="bibr">130</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>β-Secretase and cathepsin D inhibition assays, cellular Aβ production inhibition assays, viability assays, sandwich ELISA, Detection of sAPPβ by Western blot</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>BACE-1 is an aspartic protease involved in the conversion of amyloid precursor protein (APP) to Aβ in vivo, which is one of the key steps in the development and progression of AD. In a previous screening procedure for inhibitors of BACE-1 activity, the oil of 
        <italic>L. luisieri</italic> was identified as the most potent among several EOs. The overall results showed that compound 1 displayed a dose-dependent inhibition of BACE-1 in cellular and mouse models of AD and is therefore capable of passing through cellular membranes and the blood–brain barrier.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This inhibitor could be used to study functional mechanisms of BACE-1 or other aspartic proteases in cells or animal models. It could contribute to the research of disorders related to deregulation of these proteins.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">79.</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Mentha longifolia</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B131-molecules-26-01107" ref-type="bibr">131</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE)</p>
      </list-item>
      <list-item>
       <p>In vivo anti-inflammatory test—Carrageenan induced pawoedema (Wistar rats)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The EO highest yield was recorded in the spring season. Pulegone (26.92%), 1.8 cineole (21.3%), and L-menthone (10.66%) were determined as its major compounds in the winter season. In the spring oil, the main components were pulegone (38.2%) and oleic and palmitic acids (23.79% and 15.26%, respectively). A remarkable AChE inhibitory activity of the ethyl acetate fraction (Ml EtOAcF) (IC
        <sub>50</sub> = 12.3 μg/mL) and EO were also observed suggesting their neuroprotective property against AD.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>It was found that its activity level was season-dependent. Further studies are still recommended to accurately identify the bioactive molecules in this extract.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">80.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salviae aetheroleum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B8-molecules-26-01107" ref-type="bibr">8</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>We used in vitro and in vivo (the determination of SOD activity and AChE inhibitory activity) studies to fully assess its potential.</p>
      </list-item>
      <list-item>
       <p>For the in vivo testing, the EO was administered by inhalation to rats with induced AD and brain tissue samples were analysed.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The GC–MS analysis indicated the presence of 45 compounds and the principal components of the EO, in addition to thujone, were 1,8-cineole and camphor.</p>
      </list-item>
      <list-item>
       <p>The results of in vitro tests indicated that 
        <italic>S. aetheroleum</italic> is a powerful inhibitor against 15-LOX (IC
        <sub>50</sub> 0.064 µL/mL) and cholinesterase (IC
        <sub>50</sub> 0.478 µL/mL) and a good scavenger of free radicals (IC
        <sub>50</sub> 10.5 µL/mL). For the in vivo testing, daily exposures for one week to sage EO increased antioxidant enzymes activity, suggesting that the main mechanism to prevent neurodegeneration is related to antioxidant properties.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The EO extracted from dry leaves of 
        <italic>S. officinalis L.</italic> has a significant antioxidant activity. It exhibited an anticholinesterase effect. It might be used for aromatherapy in patients with Alzheimer’s dementia in order to improve the oxidative status.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">81.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">SHXW</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B132-molecules-26-01107" ref-type="bibr">132</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>SHXW EO was extracted from nine herbs.</p>
      </list-item>
      <list-item>
       <p>The mouse AD model was induced by a single injection of Aβ1–42 into the hippocampus. The animals were divided into four groups, the negative control group injected with Aβ1–42, the Aβ group injected with Aβ1–42, the SHXW group inhaled SHXW EO and received Aβ1–42 injection, and the positive control group administered with docosahexaenoic acid (DHA,10 mg/kg) and with subsequent Aβ1–42 injection.</p>
      </list-item>
      <list-item>
       <p>Mice were analysed by behavioural tests and immunological examination in the hippocampus.</p>
      </list-item>
      <list-item>
       <p>In vitro investigation was performed to examine whether SHXW EO inhibits Aβ1–42 induced neurotoxicity in a human neuroblastoma cell line, SH-SY5Y cells.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Pre-inhalation of SHXW EO improved the Aβ1–42 induced memory impairment and suppressed Aβ1–42 induced JNK, p38 and Tau phosphorylation in the hippocampus. SHXW EO suppressed Aβ-induced apoptosis and ROS production via an up-regulation of HO-1 and Nrf2 expression in SH-SY5Y cells.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>SHXW EO may have potential as a therapeutic inhalation drug for the prevention and treatment of AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">82.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Zelkova serrata</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B133-molecules-26-01107" ref-type="bibr">133</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Oxidative stress resistance assays in 
        <italic>C. elegans</italic>, 
        <italic>C. elegans</italic> paralysis assays
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The EO of 
        <italic>Z. serrata</italic> heartwood exhibited great radical scavenging activities and high total phenolic content. In vivo assays showed significant inhibition of oxidative damage in wild-type C. elegans under juglone induced oxidative stress and heat shock. Based on results from both in vitro and in vivo assays, the major compound in EO of heartwood, (−)-(1S, 4S)-7-hydroxycalamenene (1S, 4S-7HC), may contribute significantly to the observed antioxidant activity. Further evidence showed that 1S, 4S-7HC significantly delayed the paralysis phenotype in amyloid beta-expressing transgenic C. elegans.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These findings suggest that 1S, 4S-7HC from the EO of 
        <italic>Z. serrata</italic> heartwood has potential as a source for antioxidant or AD treatment.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">83.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Zingiber officinale</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B134-molecules-26-01107" ref-type="bibr">134</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Phytochemical study was carried out using semi-preparative HPLC and GC–MS systems.</p>
      </list-item>
      <list-item>
       <p>Ginger methanolic extract (GME), the isolated pure compounds and ginger EO (GEO) were tested for their inhibiting activity in vitro against AChE using Ellman’s assay.</p>
      </list-item>
      <list-item>
       <p>The methanolic extract and the EO were studied in vivo using an AD model induced in rats using oral AlCl
        <sub>3</sub>.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GME and GEO showed moderate AChE inhibitory activity in vitro. On the other hand, the treatment with GME and GEO showed improvement in the learning and memory in Alzheimer’s model induced in rats also they showed significant inhibitory activity against AChE as compared to AD group (positive control group). Moreover, they showed an improvement of the morphological structure of the brain tissue with disappearance of most amyloid plaques. The preliminary screening of different concentrations (0.25, 0.50, 1 mg/mL) of GME and GEO showed inhibitory activity in a dose-dependent manner. However, at high concentration of 1 mg/mL, GME and GEO gave 41.4 ± 0.9% and 35.0 ± 1.9% inhibition of AChE, respectively</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Study revealed the ability of GME and GEO to improve the symptoms of AD induced in rats. The inhibitory activity of both could be attributed to the presence of bioactive.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">84.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Pistacia khinjuk</italic>
     <break/>
     <italic>Allium sativum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B135-molecules-26-01107" ref-type="bibr">135</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>P. khinjuk</italic> EO(PKEO) and 
        <italic>A. sativum</italic> EO (ASEO) were prepared and analysed in terms of extraction yield, phenolic content, and cholinergic markers in vitro.
       </p>
      </list-item>
      <list-item>
       <p>Moreover, both were administered orally to adult male Wistar rats at concentrations of 1, 2, and 3%. The inhibitory potential of PKEO and ASEO was compared with Donepezil (0.75 mg/kg) against the high activities of AChE and BChE enzymes.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>PKEO reached an inhibition rate of 83.6% and 81.4% against AChE and BChE, respectively. ASEO had lower anti-cholinesterase activity (65.4% and 31.5% for the inhibition of AChE and BChE). PKEO was found to have more phenolic content than ASEO. A significantly positive correlation was observed between the total phenolics and anti-cholinesterase potential. In rats, both EO decreased the enzyme activity in a concentration-dependent manner. As compared with Donepezil, the significant difference in the AChE and BChE inhibition occurred as rats were treated with PKEO 3% (
        <italic>p</italic> &lt; 0.05).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>It could be concluded that PKEO and ASEO are potent inhibitors of AChE and BChE in rats that hold promise to be used for the treatment of AD. For future studies, it will be of interest to investigate their effect on oxidative stress in AD as one of the major cause of neurotoxicity.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">85.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>ALZHEIMER’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro and Ex vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Salvia</italic> sp
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B136-molecules-26-01107" ref-type="bibr">136</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The AChE inhibitory activity of different extracts from 
        <italic>S. trichoclada, S. verticillata</italic>, and 
        <italic>S. fruticosa</italic> was determined by the Ellman and isolated guinea pig ileum methods.
       </p>
      </list-item>
      <list-item>
       <p>The AChE inhibitory activity of the major molecule rosmarinic acid was determined by in silico docking and isolated guinea pig ileum methods.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The methanol extract of 
        <italic>S. trichoclada</italic> showed the highest inhibition on AChE. The same extract and rosmarinic acid showed significant contraction responses on isolated guinea pig ileum. All the extracts and rosmarinic acid showed high radical scavenging capacities. Docking results of rosmarinic acid showed high affinity to the selected target, AChE.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>In this study in vitro and ex vivo studies and in silico docking research of rosmarinic acid were used simultaneously for the first time. Rosmarinic acid showed promising results in all the methods tested.</p>
      </list-item>
      <list-item>
       <p>Our results suggest that rosmarinic acid may become a novel therapeutic candidate for the treatment of AD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">86.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Syzygium aromaticum</italic>
     <break/>
     <italic>Xylopia aethiopica</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B137-molecules-26-01107" ref-type="bibr">137</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
      <list-item>
       <p>TBARS—ex vivo</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>37 and 30 compounds were identified in the EOs from clove bud and Ethiopian pepper, respectively.</p>
      </list-item>
      <list-item>
       <p>High amounts of eugenol (85.61%) and β-caryophyllene (5.80%) were found in clove bud oils. Other minor components found in clove bud oils include α-caryophyllene (1.52%) and limonene (1.00%).</p>
      </list-item>
      <list-item>
       <p>The major components found in Ethiopian pepper, however, were eugenol (35.02%), terpinen-4-ol (7.21%), β-caryophyllene (5.98%), germacrene D (5.49%), (−) spathulenol (4.57%), and limonene (3.04%). The other minor components of the Ethiopian pepper oil include α-terpineol (2.71), α-caryophyllene (2.67%), β-phellandrene (2.67%), β-pinene (2.60%), eucalyptol (2.58%), β-linalool (2.28%) and α-pinene (1.75%).</p>
      </list-item>
      <list-item>
       <p>The EOs also inhibited AChE and BChE activities in a concentration-dependent manner (7.7–23.1 µL/L). Both oils were observed to have a stronger inhibitory effect on AChE than BChE. Furthermore, eugenol was identified as the major component in both EOs.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These results reveal the clove bud and Ethiopian pepper oils as potential sources of active metabolites with cholinesterase and antioxidant properties, although the Ethiopian pepper EO showed better potentials.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">87.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cinnamomum verum</italic>
     <break/>
     <italic>Cinnamomum cassia</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B138-molecules-26-01107" ref-type="bibr">138</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The cytotoxicity and cell apoptosis has been induced by 6-OHDA in PC12 cells. The protective effect was determined by measuring cell viability, the amount of reactive oxygen species (ROS), and apoptosis.</p>
      </list-item>
      <list-item>
       <p>Cell viability and apoptosis were assessed using resazurin assay, flow cytometry of propidium iodide (PI) stained cells, and Western blot analysis</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>6-OHDA resulted in the death and apoptosis of cells while, pretreatment with the extract and EOs of 
        <italic>C. verum</italic> and 
        <italic>C. cassia</italic> at 20 µg/mL and cinnamaldehyde at 5 and 10 µM for 24 h could significantly increase the viability (
        <italic>p</italic> &lt; 0.001), and decrease ROS content (
        <italic>p</italic> &lt; 0.05). Pretreatment with the extracts increased survivin and decreased cyt-c whereas pretreatment with the EOs decreased cyt-c, increased survivin, and reduced P-p44/42/p44/42 levels to a level near that of the related control. The extract and EOs of 
        <italic>C. verum</italic> and 
        <italic>C. cassia</italic> can be effective against 6-OHDA cytotoxicity.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>It is suggested that, the synergistic efects of cinnamaldehyde and other components of extract and EOs promote cinnamon’s medicinal properties. Our study suggests that cinnamon components may be considered as neuroprotective agents in PD treatment.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">88.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Eryngium</italic> sp.
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B139-molecules-26-01107" ref-type="bibr">139</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>MAO inhibition assay</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>EFEO, EEEO, ENEO, EHEO, and EPEO GC–MS analysis showed (E)-caryophyllene (4.9–10.8%), germacrene 
        <sc>d</sc> (0.6–35.1%), bicyclogermacrene (10.4–17.2), spathulenol (0.4–36.0%), and globulol (1.4–18.6%) as main constituents.
       </p>
      </list-item>
      <list-item>
       <p>None of the EO inhibited MAO-A activity (4 and 40 µg/mL). However, EHEO inhibited MAO-B activity with an IC
        <sub>50</sub> value of 5.65 mg/mL (1–200 mg/mL). Pentadecane (10 mM), its major constituent (53.5%), did not display significant MAOB inhibition.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The study demonstrates the promising application of Eryngium species as a source of potential central nervous system bioactive secondary metabolites, specially related to neurodegenerative disorders.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">89.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Myrtus communis</italic>
     <break/>
     <italic>Ferula gummosa</italic>
     <break/>
     <italic>Eucalyptus globulus</italic>
     <break/>
     <italic>Satureja hortensis</italic>
     <break/>
     <italic>Rosmarinus officinalis</italic>
     <break/>
     <italic>Mentha spicata</italic>
     <break/>
     <italic>Mentha piperita</italic>
     <break/>
     <italic>Cuminum cyminum</italic>
     <break/>
     <italic>Artemisia dracunculus</italic>
     <break/>
     <italic>Citrus sinensis</italic>
     <break/>
     <italic>Citrus limonum</italic>
     <break/>
     <italic>Thymus vulgaris</italic>
     <break/>
     <italic>Lavandula officinalis</italic>
     <break/>
     <italic>Mentha pulegium</italic>
     <break/>
     <italic>Foeniculum vulgare</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B140-molecules-26-01107" ref-type="bibr">140</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The fibrillation process was monitored by thioflavin T fluorescence intensity.</p>
      </list-item>
      <list-item>
       <p>According to an increase in the permeabilisation of vesicles in the presence of the toxic aggregated species including oligomers and protofibrils, release of calcein from liposomes and the subsequent increase in the fluorescence signal due to dilution were measured.</p>
      </list-item>
      <list-item>
       <p>The MTT assay for cell viability evaluations.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>M. communis</italic> particularly increased α-Syn fibrillation in a concentration-dependent manner. By using a unilamellar vesicle, it was shown that the aggregated species with tendency to perturb membrane were increased in the presence of 
        <italic>M. communis</italic>. In this regard, the cytotoxicity of α-Syn on SH-SH5Y cells was also increased significantly. Inappropriately, the effects of fibrillation inhibitors, baicalein and cuminaldehyde, were modulated in the presence of 
        <italic>M. communis</italic>. However, major components of 
        <italic>M. communis</italic> did not induce fibrillation and also the effect of 
        <italic>M. communis</italic> was limited on other fibrinogenic proteins.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Assuming that EOs have the ability to pass through the blood brain barrier along with the popular attention on aromatherapy for the incurable ND, these findings suggest an implementation of fibrillation tests for EOs.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">90.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Cuminum cyminum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B141-molecules-26-01107" ref-type="bibr">141</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Site-directed mutagenesis of human α-SN and labeling with MBBr, Protein labeling with Fluorescein isothiocyanate (FITC)</p>
      </list-item>
      <list-item>
       <p>α-SN fibrillation process was monitored by Thioflavin T fluorescenceintensity</p>
      </list-item>
      <list-item>
       <p>Fractionation of 
        <italic>C. cyminum</italic> (silica gel chromatography) and investigation the influences of the fractions on the α-SN fibril formation
       </p>
      </list-item>
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Discriminating apoptosis/necrosis using double stainingflow cytometric assay</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Analysis of different fractions from the total extract identified cuminaldehyde as the active compound involved in the anti-fibrillation activity.</p>
      </list-item>
      <list-item>
       <p>In comparison with baicalein, a well-known inhibitor of α-SN fibrillation, cuminaldehyde showed the same activity in some aspects and a different activity on other parameters influencing α-SN fibrillation.</p>
      </list-item>
      <list-item>
       <p>The presence of spermidine, an α-SN fibrillation inducer, dominantly enforced the inhibitory effects of cuminaldehyde even more intensively than baicalein.</p>
      </list-item>
      <list-item>
       <p>Cuminaldehyde prevents α-SN fibrillation even in the presence of seeds, having no disaggregating impact on the preformed fibrils.</p>
      </list-item>
      <list-item>
       <p>Cytotoxicity assays on PC12 cells showed that cuminaldehyde is a nontoxic compound, treatment with cuminaldehyde throughout α-SN fibrillation showed no toxic effects on the cells.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Cuminaldehyde can modulate α-SN fibrillation. have potential therapeutic applications.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">91.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Acorus tatarinowii Schott</italic> (Shi Chang Pu)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B142-molecules-26-01107" ref-type="bibr">142</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>To prove the hypothesis, we investigated the mRNA levels of glucose regulated protein 78 (GRP78) and C/EBP homologous binding protein (CHOP) in 6-hydroxydopamine (6-OHDA) induced parkinsonian rats after β-asarone treatment. Furthermore, the inositol-requiring enzyme 1/X-Box Binding Protein 1 (IRE1/XBP1) ER stress pathway was also studied.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>β-asarone could improve the behaviour of parkinsonian rats; increase the HVA, Dopacl, and 5-HIAA levels; and reduce α-synuclein levels. Here, we assumed that the protective role of β-asarone on parkinsonian rats was mediated via the ER stress pathway. β-asarone inhibited the mRNA levels of GRP78 and CHOP, accompanied with the declined expressions of phosphorylated IER1 (p-IRE1) and XBP1. We deduced that β-asarone might have a protective effect on the 6-OHDA induced parkinsonian rats via IRE1/XBP1 Pathway</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Collectively, all data indicated that β-asarone might be a potential candidate of medicine for clinical therapy of PD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">92.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Acorus tatarinowii Schott</italic> (Shi Chang Pu)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B143-molecules-26-01107" ref-type="bibr">143</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>To support this hypothesis, we investigated the expressions of glucose regulated protein 78 (GRP78), PERK phosphorylation (p-PERK), C/EBP homologous binding protein (CHOP), Bcl-2 and Beclin-1 in 6-OHDA-induced parkinsonian rats after β-asarone treatment.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results showed that the β-asarone group and PERK inhibitor group had lower levels of GRP78, p-PERK, CHOP and Beclin-1 while having higher levels of Bcl-2.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>β-asarone might regulate the ER stress-autophagy via inhibition of the PERK/CHOP/Bcl-2/Beclin-1 pathway in 6-OHDA-induced parkinsonian rats.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">93.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Eplingiella fruticosa</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B144-molecules-26-01107" ref-type="bibr">144</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS).</p>
      </list-item>
      <list-item>
       <p>We evaluated the effects of EO (EPL) and EPL complexed with β-cyclodextrin EPL-βCD (5 mg/kg, p.o. for 40 days) on male mice submitted to the progressive reserpine PD model. Behavioural evaluations, lipid peroxidation quantification and immunohistochemistry for tyrosine hydroxylase were conducted.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Phytochemical analysis showed the main constituents comprised β-caryophyllene, bicyclogermacrene and 1,8-cineole.</p>
      </list-item>
      <list-item>
       <p>EPL delayed the onset of catalepsy and decreased membrane lipid peroxides levels in the striatum. EPL-βCD also delayed the onset of catalepsy, reduced the frequency of oral dyskinesia, restored memory deficit, produced anxiolytic activity and protected against dopaminergic depletion in the striatum and substantia nigra pars compacta (SNpc).</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These findings showed that EPL has a potential neuroprotective effect in a progressive PD animal model. Furthermore, EPL-βCD enhanced this protective effects, suggesting a novel therapeutic approach to ameliorate the symptoms of PD.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">94.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Foeniculum vulgare</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B145-molecules-26-01107" ref-type="bibr">145</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>To create a model of Parkinson’s drug reserpine subcutaneously at a rate of 3 mg was used. Rats were surgically ovariectomized. Ten groups, each consisting of 8 rats, were used. The authors studied a total of 48 ovariectomized rats. EO of fennel (50, 100, 200 mg/kg) were used for treatment for 5 days. After the 5 days of behavioural and motor tests were performed, the amount of oestrogen was measured.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>In this study, rats were ovariectomized and fennel EO doses (50, 100, 200 mg/kg) significantly increased amounts of oestrogen. The motor disorders of the treated groups were reduced. Furthermore, the non-ovariectomized groups were treated with EO of fennel. The amount of oestrogen increased and motor activity as well as behaviour had improved in the control groups.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The present study affirms that EO of fennel improve Parkinson’s in animal models. Further studies are needed to demonstrate the possible effects of EO of fennel on individuals with Parkinson’s and postmenopausal women.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">95.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Pulicaria undulata</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B146-molecules-26-01107" ref-type="bibr">146</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS)</p>
      </list-item>
      <list-item>
       <p>The neuroprotective effects of three dose levels (50, 100, and 200 mg/kg) of 
        <italic>P. undulata</italic> EO (PUEO) in rotenone-induced model in male Wistar rats were investigated.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Carvotanacetone was the major component (80.14%).</p>
      </list-item>
      <list-item>
       <p>The middle and high doses of PUEO attenuated rotenone-induced behavioural deficits besides, hindering the decrease in striatal dopamine and ATP levels, with partial retardation in rotenone-induced body weight loss. Biochemical assessments illustrated that PUEO mitigated rotenone-induced increment in striatal interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and inducible nitric oxide synthase (iNOS). The reduction in malondialdehyde and increase in glutathione striatal contents depicted its antioxidant potential. Molecular docking study of carvotanacetone might justify the observed normalisation of the elevated iNOS level induced after exposure to rotenone.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>This is the first study indicating the ability of PUEO to protect rats against rotenone-induced PD via anti-inflammatory and antioxidant activities with the ability to reduce α-synuclein gene expression.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">96.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Zingiber officinale</italic>
     <break/>
     <italic>Syzygium aromaticum</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B28-molecules-26-01107" ref-type="bibr">28</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) Levels, SOD activity, CAT activity, GPx activity, GSH and Ascorbic determination.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Daily oral administration of eugenol/zingerone and injection of L-dopa intraperitoneally for 4 weeks following a single 6-OHDA injection did not improve abnormal behaviours induced by L-dopa treatment. 6-OHDA reduced the DA level in the striatum; surprisingly, zingerone and eugenol enhanced the reduction in striatal DA and its metabolites. Zingerone decreased catalase activity, and increased glutathione peroxidase activity and the oxidised L-ascorbate level in the striatum.Previously reported findings showed that pre-treatment with zingerone or eugenol prevents 6-OHDA-induced DA depression by preventing lipid peroxidation. However, the present study shows that post-treatment with these substances enhanced the DA decrease. These substances had adverse effects dependent on the time of administration relative to model PD onset.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These results suggest that we should be wary of ingesting these spice elements after the onset of PD symptoms.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">97.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro and In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>SHXW</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B147-molecules-26-01107" ref-type="bibr">147</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Cell toxicity, apoptosis, and ROS levels were analysed in the human neuroblastoma cell line SH-SY5Y.</p>
      </list-item>
      <list-item>
       <p>After that, changes in animal behaviour and tyrosine hydroxylase (TH) protein levels in the substantia nigra (SN) of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-injected mice were examined.</p>
      </list-item>
      <list-item>
       <p>Three different doses of KSOP1009 (30, 100, and 300 mg/kg, 
        <italic>n</italic> = 8 for each group) were administered daily for 7 d before MPTP injection and 14 d after MPTP injection, totaling 21 d.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>MPP+, the active metabolite of MPTP, decreased the viability of SH-SY5Y cells, whereas KSOP1009 alleviated MPP+-induced cytotoxicity. KSOP1009 (10 and 50 mg/mL) reduced MPP+-induced ROS generation compared with the control group. Treatment with 1 mM MPP+ increased the percentage of depolarised/live cells, whereas KSOP1009 intake at a dose of 10 mg/mL decreased the percentage of these cells.</p>
      </list-item>
      <list-item>
       <p>The mean latency to fall in the rotarod test was reduced in mice treated with MPTP compared with the control group. However, mice receiving three different doses of KSOP1009 performed better than MPTP-treated animals. MPTP-treated mice were more hesitant and took longer to traverse the balance beam than the control animals. In contrast, KSOP1009-treated mice performed significantly better than MPTP-treated mice. Furthermore, the KSOP1009-treated groups had a significantly higher number of TH-positive neurons in the lesioned SN and significantly higher expression of TH in the striatum than the MPTP-treated group. MPTP treatment strongly induced Jun-N-terminal kinase (JNK) activation, whereas KSOP1009 suppressed MPTP-induced JNK activation. In addition, KSOP1009 intake reversed the decrease in the phosphorylation levels of cAMP-response element-binding protein in the brain of MPTP-treated mice. KSOP1009 also restored the decrease in dopaminergic neurons and dopamine levels in the brain of MPTP-treated mice.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>KSOP1009 protected mice against MPTP-induced toxicity by decreasing ROS formation and restoring mitochondrial function.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">98.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo and ex vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Rosa damascena Mill.</italic>
     <break/>
     <italic>Lavandula angustifolia Mill,</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B148-molecules-26-01107" ref-type="bibr">148</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Male non-inbred albino mice (25–40 g) were divided into six groups. The groups undergoing combination therapy were pre-treated first for one hour with i.p. injections in doses of 400 mg/kg of ascorbic acid, Trolox, rose oil or lavender oils and received L-dopa and benserazide.</p>
      </list-item>
      <list-item>
       <p>The antioxidants protective effects against L-dopa oxidative by the levels of the three biomarkers of oxidative stress (OS)—MDA reactive substances, protein carbonyl content (PCC) and NO radicals in brain homogenate and blood of experimental mice.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Statistically significant increase relative to controls were observed in the combination rose oil + L-dopa (mean 3.06 ± 0.28 nmol/mL vs mean 1.51 ± 0.07 nmol/mL, 
        <italic>p</italic> &lt; 0.05, 
        <italic>t</italic>-test).
       </p>
      </list-item>
      <list-item>
       <p>Similar results were seen in combinations of lavender oil + L-dopa, statistically significantly higher than controls (mean 3.74 ± 0.21 nmol/mL vs mean 1.51 ± 0.07 nmol/mL, 
        <italic>p</italic> &lt; 0.05, 
        <italic>t</italic>-test)
       </p>
      </list-item>
      <list-item>
       <p>The levels of MDA in the combinations of rose oil + L-dopa were slightly higher vs controls (mean 2.11 ± 0.1 μmol/mL vs mean 1.88 μmol/mL ± 0.02, 
        <italic>p</italic> &lt; 0.1, 
        <italic>t</italic>-test), and was statistically lower than the samples of mice treated with L-dopa (mean 2.11 ± 0.11 μmol/mL vs mean 2.87 ± 0.07 μmol/mL, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test).
       </p>
      </list-item>
      <list-item>
       <p>The combination lavender oil + L-dopa showed a statistically significant increase in comparison with the controls (mean 2.05 ± 0.15 μmol/mL vs mean 1.88 ± 0.02 μmol/mL, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test), and compared to samples treated only with L-dopa observed a statistically significant decrease (mean 2.05 ± 0.15 μmol/mL compared to an average of 2.87 ± 0.07 μmol mL, 
        <italic>p</italic> &lt; 0.3, 
        <italic>t</italic>-test).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Study suggests that combination of EOs (rose oil and lavender oil), vitamin C and Trolox with L-dopa can reduce oxidative toxicity, and may play a key role in ROS/RNS disarming.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">99.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>PARKINSON’S DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo and ex vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Rosa Damascena Mill.</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B149-molecules-26-01107" ref-type="bibr">149</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Male non-inbred albino mice (25–40 g) and were divided into four groups. The control group of mice was inoculated two i.p. injections with solvent, only. The second injection was administered 45 min after the first.</p>
      </list-item>
      <list-item>
       <p>To study the L-dopa effect we used the acute model. The mice from all tested groups (except controls) received either two i.p. injections of L-dopa (100 mg/kg) followed by benserazide (10 mg/kg). The second injection was administered 45 min after the first. The groups undergoing combination therapy were pre-treated first for 1 h with i.p. injections with ascorbic acid (400 mg/kg), rose oil (400 mg/kg) and after that received L-dopa and benserazide. All mice were sacrificed by light anesthesia (Nembutal 50 mg/kg i.p.) after 30 min.</p>
      </list-item>
      <list-item>
       <p>Levels of lipid peroxidation measured as MDA, Protein carbonyl content (PCC), and advanced glycation end products (AGEs) in blood plasma of experimental model of healthy mice</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Statistically significant increased MDA levels, PCC and AGEs were found in the blood L-dopa treated mice compared to the controls, while the same parameters were significantly decreased in the group pre-treated with antioxidants compared to the same controls.</p>
      </list-item>
      <list-item>
       <p>The MDA level in the combination L-dopa + ascorbic acid was statistically significantly higher than in controls (mean 2.08 ± 0.04 μmol/mL vs mean 1.77 ± 0.03 μmol/mL, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test) and statistically significantly lower than in mice treated with L-dopa alone (mean 2.08 ± 0.04 μmol/mL vs mean 3.75 ± 0.12 μmol/mL, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test).
       </p>
      </list-item>
      <list-item>
       <p>MDA level in combination L-dopa + Rose oil is statistically significantly higher than controls (mean 2.16 ± 0.05 μmol/mL vs mean 1.77 ± 0.03 μmol/mL, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test), and statistically lower than samples treated with L-dopa alone (mean 2.16 ± 0.05 μmol/mL vs mean 23.75 ± 0.12 μmol/mL, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test).
       </p>
      </list-item>
      <list-item>
       <p>Statistically significant increase in PCC is observed in group treated with L-dopa + Ascorbic acid versus controls (mean 3.18 ± 0.09 nmol/mg vs mean 1.55 ± 0.04 nmol /mg, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test), but compared with group treated with L-dopa alone, the PCC level was statistically significant lower (mean 3.18 ± 0.09 nmol/mg vs. 5.23 ± 0.01 nmol/mg, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test).
       </p>
      </list-item>
      <list-item>
       <p>The L-dopa + rose oil combination compared to controls was statistically significantly higher (mean 3.07 ± 0.02 nmol/mg vs. mean 1.55 ± 0.04 nmol/mg, 
        <italic>p</italic> &lt; 0.00, 
        <italic>t</italic>-test), and statistically significantly lower in samples treated with L-dopa alone (mean 3.07 ± 0.02 nmol/mg vs. mean 5.23 ± 0.35 nmol/mg, 
        <italic>p</italic> &lt; 0.00, t-test).
       </p>
      </list-item>
      <list-item>
       <p>Ascorbic acid + L-dopa (686 ± 21.6 μg/mL, vs 432 ± 19.05 μg/mL, 
        <italic>p</italic> &lt;.00, 
        <italic>t</italic>-test), and rose oil + L-dopa (489 ± 13.1 μg/mL, vs 432 ± 19.05 μg/mL, 
        <italic>p</italic> &lt; 0.000, 
        <italic>t</italic>-test). Both groups pretreated with antioxidants showed a statistically significant decrease compared to group treated with L-dopa alone (
        <italic>p</italic> &lt; 0.00).
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The studied antioxidants can protect organisms from induced L-dopa oxidative toxicity and may play a key role in end products protection.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">100.</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">
     <bold>OTHER NEURODEGENERATIVE DISEASE</bold>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Lavandula pedunculata subsp lusitanica</italic> (Chaytor) Franco
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B150-molecules-26-01107" ref-type="bibr">150</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS, HPLC-DAD)</p>
      </list-item>
      <list-item>
       <p>TBARS assay</p>
      </list-item>
      <list-item>
       <p>Cholinesterase inhibition assay (AChE, BChE—Ellman assay)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GC–MS analysis revealed that oxygen-containing monoterpenes was the principal group of compounds identified in the EO. Camphor (40.6%) and fenchone (38.0%) were found as the major constituents. HPLC–DAD analysis allowed the identification of hydroxycinnamic acids (3-O-caffeoylquinic, 4-O-caffeoylquinic, 5-O-caffeoylquinic and rosmarinic acids) and flavones (luteolin and apigenin) in the polar extracts, with rosmarinic acid being the main compound in most of them.</p>
      </list-item>
      <list-item>
       <p>The bioactive compounds from 
        <italic>L. pedunculata</italic> polar extracts were the most efficient free-radical scavengers, Fe
        <sup>2+</sup> chelators and inhibitors of malondialdehyde production, while the EO was the most active against AChE.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Subspecies of 
        <italic>L. pedunculata</italic> is a potential source of active metabolites with a positive effect on human health. This research suggests 
        <italic>L. pedunculata subsp. lusitanica</italic> as a source of natural compounds able to prevent neurodegenerative diseases.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">101.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Pelargonium graveolens</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B151-molecules-26-01107" ref-type="bibr">151</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–MS)</p>
      </list-item>
      <list-item>
       <p>Preparation of primary cultures of microglial cells, nitrite quantification, Western blot analysis</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GC–MS analysis revealed presence of citronellol (26%), citronellyl formate (16%), linalool (10%), geraniol (8%), isomenthone (6%), and menthone (4%).</p>
      </list-item>
      <list-item>
       <p>Geranium oil inhibited NO production, as well as the expression of the proinflammatory enzymes cyclooxygenase-2 (COX-2) and induced nitric oxide synthase (iNOS) in primary cultures of activated microglial cells. When tested at natural relative concentrations in the oil, none of the major constituents of the oil could inhibit NO production. At higher concentrations, citronellol exhibited an inhibitory activity.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The results suggest a possible synergistic interaction between these components. Thus, geranium oil might be beneficial in the prevention/treatment of neurodegenerative diseases where neuroinflammation is part of the pathophysiology.</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">102.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>OTHER NEURODEGENERATIVE DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Myrcianthes myrsinoides</italic> (Kunth) 
     <italic>Grifo</italic>
     <break/>
     <italic>Myrcia mollis</italic> (Kunth) DC. (Myrtaceae)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B152-molecules-26-01107" ref-type="bibr">152</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Chemical profiling (GC–FID, GC–MS), enantioselective gas chromatography, and gas chromatography–olfactometry (GC–O)</p>
      </list-item>
      <list-item>
       <p>Anticholinesterase activity (AChE, BChE)</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>A total of 58 compounds for 
        <italic>Myrcianthes myrsinoides</italic> EO and 22 compounds for 
        <italic>Myrcia mollis</italic> EO were identified and quantified by GC–MS with apolar and polar columns (including undetermined components). Major compounds (&gt; 5.0%) were limonene (5.3–5.2%), 1,8-cineole (10.4–11.6%), (Z)-caryophyllene (16.6–16.8%), 
        <italic>trans</italic>-calamenene (15.9–14.6%), and spathulenol (6.2–6.5%). The enantiomeric excess of eight chiral constituents was determined, being enantiomerically pure (+)-limonene and (+)-germacrene D. Eight components were identified as determinant in the aromatic profile: α-pinene, β-pinene, (+)-limonene, γ-terpinene, terpinolene, linalool, β-elemene and spathulenol. For 
        <italic>M. mollis</italic>, the major compounds (&gt; 5.0%) were α-pinene (29.2–27.7%), β-pinene (31.3–30.0%), myrcene (5.0–5.2%), 1,8-cineole (8.5–8.7%), and linalool (7.7–8.2%). The enantiomeric excess of five chiral constituents was determined, with (S)-α-pinene and (+)-germacrene D enantiomerically pure.
       </p>
      </list-item>
      <list-item>
       <p>Finally, the 
        <italic>M. myrsinoides</italic> EO has an inhibitory activity for cholinesterase enzymes (IC
        <sub>50</sub> of 78.6 µg/mL and 18.4 µg/mL vs. AChE and BChE, respectively.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>M. myrsinoides</italic> and 
        <italic>M. mollis</italic> have different chemical compositions. The similarity in the aroma extract dilution analysis evaluation could justify the similarity. This activity is of interest to treat AD.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-left:solid thin;border-right:solid thin" rowspan="1" colspan="1">103.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <bold>OTHER NEURODEGENERATIVE DISEASE</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">In vivo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <italic>Anthriscus nemorosa</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">[
     <xref rid="B153-molecules-26-01107" ref-type="bibr">153</xref>]
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>
        <italic>Anthriscus nemorosa</italic> EO was administered by inhalation in the doses of 1% and 3% for 21 continuous days and scopolamine (0.7 mg/kg) was injected intraperitoneally 30 min before the behavioural testing. Y-maze and radial arm-maze tests were used for assessing memory processes. Additionally, the anxiety and depressive responses were studied by elevated plus-maze and forced swimming tests.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The scopolamine alone-treated rats exhibited the following: decrease the percentage of the spontaneous alternation in Y-maze test, increase the number of working and reference memory errors in radial arm-maze test, decrease in the exploratory activity, the percentage of the time spent and the number of entries in the open arm within elevated plus-maze test and decrease in swimming time and increase in immobility time within forced swimming test. However, dual scopolamine and 
        <italic>A. nemorosa</italic> EO-treated rats showed significant improvement of memory formation and exhibited anxiolytic- and antidepressant-like effects in scopolamine-treated rats.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin;border-right:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>These results suggest that 
        <italic>A. nemorosa</italic> EO inhalation can prevent scopolamine-induced memory impairment, anxiety and depression.
       </p>
      </list-item>
     </list>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
